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SUMMARY 
 
Prostate cancer (PCa) is the second most frequent malignancy in men worldwide and 
a common cause of cancer related mortality, constituting a frightening global health problem. 
The multifocal and highly heterogeneous nature of PCa increases the difficulty to study its 
progression and to define the most effective prevention strategies or treatment options. The 
lack of accurate methods able to differentiate between slow-growing tumors of no clinical 
significance and aggressive carcinomas has reinforced the need of unveiling the underlying 
molecular genetic alterations and pathways behind prostate cancer initiation and 
tumorigenesis. 
An important breakthrough in the search for novel pathogenic mechanisms in the field 
of PCa was the finding of chromosomal rearrangements, responsible for de formation gene 
fusions involving the ETS family of transcription factors. The TMPRSS2-ERG is the most 
frequent type of chromosomal rearrangement present in nearly 50% of localized PCa and in 
21% of precursor HGPIN lesions, followed by the ETV1, ETV4, ETV5 and FLI1 genes fused 
with one of several additional 5´fusion partners. Although ETS fusion genes represent an 
early event in PCa, secondary copy number changes, such as 8q gain including the MYC 
oncogene, have been shown to be more relevant as prognostic factors. In fact, relative 8q 
gain is a poor prognostic factor irrespective of TMPRSS2-ERG fusion gene status in 
diagnostic needle biopsy specimens from PCa patients. Moreover, recent integrated 
analyses of genome and transcriptome led to the discovery of a C15orf21-MYC fusion in a 
single case of hybrid and aggressive case of PCa.  
The main aim of this thesis was to explore the role of MYC relative copy number 
increase and structural rearrangements in a set of 50 prostatectomy specimens from patients 
with clinically localized prostate carcinoma, with available genome-wide microarray 
expression data. To achieve this goal, a FISH break-apart probe strategy using BAC clones 
flanking MYC and a chromosome 18 centromeric probe, to control of ploidy, was used. 
Overall, tumor cell populations displaying MYC relative copy number increase 
(MYC/CEP18≥1.5) were found in 35% of the prostatectomy specimens and one PCa 
presented a deletion of the 5´MYC region, which may be indicative of MYC a rearrangement 
involving a 5´fusion partner. Additionally, we confirmed the involvement of MYC in 4 PCa 
biopsy specimens with available data indicating a structural rearrangement in 8q24. A probe 
strategy using BAC clones targeting the 5´ region of C15orf21 and the 3´region of MYC was 
also used, but C15orf21 is not the 5’ fusion partner in these cases. 
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In order to identify genes with differential expression among the two FISH subgroups 
(presence or absence of 8q relative gain), a significance analysis of microarrays (SAM) was 
used. Gene expression results highlighted three significantly overexpressed genes in the 
subgroup of patients with 8q relative gain, namely IKZ2, CDON and GPRC5A (FDR=0% and 
q-value=0%) and all of these are annotated to play a role in cancer, being up-regulated 
(IKZF2 and CDON) or, in the case of GPRC5A, being both up- and down-regulated. 
According to SAM analysis, MYC was not found to be differentially expressed among the two 
subgroups of patients (q-value = 35), but it showed a tendency to present higher expression 
among those with relative copy number gain (P = 0.051). To look for the possible effect of 
ETS rearrangements status in MYC expression, we compared three groups of patients 
harboring no ETS rearrangements, an ERG fusion gene, or other ETS rearrangements 
(ETV1, ETV4 and ETV5) in the presence or absence of 8q gain. A significantly differential 
expression of MYC among the different ETS rearrangements groups of patients was 
observed only in the patients with no 8q gain (P=0.048), and paired comparisons showed 
that MYC expression was significantly higher in the group of patients with ETS 
rearrangements other than ERG (P=0.021) compared with ETS negative patients.
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RESUMO 
 
O cancro da próstata constitui a segunda neoplasia mais frequente em homens em 
todo o mundo e é uma causa comum de mortalidade, representando um importante 
problema de saúde pública. A natureza multifocal e altamente heterogénea desta doença 
aumenta a dificuldade de estudo da sua progressão, bem como da definição de estratégias 
mais eficazes, ou melhores formas de tratamento. A falta de métodos mais exactos, capazes 
de diferenciar entre tumores indolentes e clinicamente insignificantes e carcinomas mais 
agressivos, reforçam a necessidade de desvendar as alterações genéticas e vias de 
sinalização subjacentes à carcinogénese prostática. 
Uma importante descoberta, na procura de novos mecanismos patológicos na área 
do cancro da próstata, foi a identificação de rearranjos cromossómicos, responsáveis pela 
formação de genes de fusão a envolver a família dos factores de transcrição ETS. O 
TMPRSS2-ERG é o rearranjo cromossómico mais frequente, estando presente em quase 
metade dos tumores de próstata localizados e em 21% das lesões percursoras HGPIN, 
seguido do ETV1, ETV4, ETV5 e FLI1, geralmente rearranjados com um dos vários 
parceiros 5´adicionais. Apesar dos genes de fusão ETS representarem um evento precoce 
em cancro da próstata, alterações secundárias do número de cópias, tal como o ganho do 
8q, incluindo o gene MYC, foram demonstradas como sendo mais relevantes em termos de 
factor de prognóstico. De facto, o ganho relativo do 8q é um factor de mau prognóstico, 
independente do status do gene de fusão TMPRSS2-ERG em biópsias de pacientes com 
cancro da próstata. Para além disso, e mais recentemente, análises integradas do genoma e 
transcriptoma conduziram à descoberta do gene de fusão C15orf21-MYC num único caso de 
cancro da próstata híbrido e agressivo.  
O principal objectivo desta foi explorar o papel do aumento relativo do número de 
cópias do MYC, bem como de rearranjos estruturais envolvendo este gene numa série de 50 
prostatectomias, de pacientes com cancro da próstata localizado, com dados disponíveis 
sobre a expressão global do genoma por microarray. 
 Assim, foi feita uma estratégia de análise por FISH com uma sonda break-apart 
incluindo BAC clones, que flanqueavam o gene MYC, e uma sonda centromérica do 
cromossoma 18, para controlo da ploidia. No total, as populações de células tumorais que 
apresentavam aumento relativo do número de cópias do MYC foram encontradas em 35% 
das prostatectomias e uma prostatectomia apresentava uma delecção da região 5´do MYC, 
o que pode ser indicativo de um rearranjo do MYC envolvendo um parceiro de fusão 5´. 
Confirmámos adicionalmente o envolvimento do gene MYC em 4 biópsias de cancro da 
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próstata com dados disponíveis que indicavam um rearranjo estrutural na região 8q24. Uma 
estratégia de sondas utilizando BAC clones, tendo como alvo a região 5´ do gene C15orf21 
e a região 3´ do gene MYC foi usada, mas o gene C15orf21 não é o parceiro de fusão 5´ 
nestes casos. 
A fim de identificar genes diferencialmente expressos nos dois grupos de FISH 
(presença ou ausência do ganho relativo do 8q), foi utilizada uma análise de significância do 
micoarray de expressão (SAM). Os resultados do perfil de expressão destacaram 3 genes 
significativamente sobre-expressos no subgrupo de pacientes com ganho relativo do 8q, 
nomeadamente IKZF2, CDON e GPRC5A (FDR = 0%, q-value = 0%) e todos eles estão 
descritos como tendo um papel no cancro, estando sobre- expressos (IKZF2 e CDON), ou, 
no caso do GPRC5A, estando tanto sub - como sobre-expresso. De acordo com a análise 
por SAM, o gene MYC não foi encontrado diferencialmente expresso nos dois subgrupos de 
pacientes (q – value = 35), mas demonstrou uma tendência para apresentar uma maior 
expressão nos pacientes com aumento relativo do número de cópias (P = 0.051). Para 
analisarmos o possível efeito do status de rearranjos ETS na expressão do MYC, 
comparamos três grupos de pacientes sem evidência de rearranjos ETS, com um gene de 
fusão envolvendo o ERG, ou tendo outros rearranjos ETS (ETV1, ETV4 e ETV5) na 
presença ou ausência do ganho do 8q. A expressão do MYC foi significativamente 
diferencial entre os diferentes grupos ETS, unicamente no grupo de pacientes com o ganho 
do 8q (P=0.048) e comparações emparelhadas demonstraram que a expressão do MYC foi 
mais elevada no grupo de pacientes com rearranjos de outros ETS, que não o ERG 
(P=0.021), quando comparado com os pacientes sem rearranjos ETS. 
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INTRODUCTION 
 
1. Cancer: A Doubtless Major Health Problem 
Cancer is a frightening global health problem and it has been quite concerning to see 
the large increase of this burden. According to GLOBOCAN 2008 estimative, about 12.7 
million new cancer cases and 7.6 million deaths have occurred worldwide. 
Being a group of diseases, cancer is characterized by uncontrolled growth and 
spread of abnormal cells. Cancer is the final product of the synergistic or sequential effect of 
both external (tobacco, infectious organisms, chemicals and radiation), and internal (inherited 
mutations, hormones, immune conditions) factors. 
This human genetic disease is caused by genetic alterations inactivating tumor 
suppressor genes (TSGs) as well as DNA repair genes, and activating oncogenes (Hanahan 
and Weinberg, 2000; Porkka and Visakorpi, 2004). Most of the mutations are acquired during 
cancer progression and are thus considered to be mechanisms of tumorigenesis. On the 
other hand, some mutations may be inherited, resulting in predisposition to cancer. However, 
about ten or more years often pass between exposure to external factors and detectable 
cancer.  
The rational for studying the molecular mechanisms behind the development of 
malignancies is that they may provide means for better diagnostics, prognostics and 
treatment of cancer. These topics will be discussed in more detail later on. 
 
 
1.1 Prostate cancer epidemiology 
Prostate cancer (PCa) contributes to the overall cancer burden and continues to 
represent a significant challenge to the clinical community worldwide, being the second most 
frequently diagnosed non-skin cancer in men worldwide and the sixth deadliest cancer, 
totalizing 903,500 new cancer cases and 258,400 new cancer-related deaths (Jemal et al., 
2011). The low fatality means that many men are alive following a diagnosis of PCa. 
Interestingly, both developed and developing countries differ widely in terms of 
incident and mortality rates, recording higher incidence mainly in Oceania, Western and 
Northern Europe and North America (Figure 1). Prostate cancer remains relatively rare in 
Asian population. Incident rates reflect not only differences in risk of disease, but also the 
extent of diagnosis of latent cancers both by screening of asymptomatic individuals - practice 
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of prostate-specific antigen (PSA) screening which enables a better and earlier diagnosis – 
and subsequent biopsy or even by detection of latent cancer in tissue removed during
prostatectomy operations or at autopsy (Eble et al., 2004). In contrast, epidemiological data 
indicates that black males of African descendent in the Caribean and Jamaica regions and 
African American men have the highest documented PCa mortality rates in the world (Jemal 
et al., 2011), followed by white people, who in turn have rates considerably higher than Asian 
populations (including Chinese, Japanese and Korean males) (Eble et al., 2004). Differences 
in genetic factors (Corder et al., 1995; Devgan et al., 1997; Irvine et al., 1995; Platz et al., 
2000; Shook et al., 2007), along with levels of sex hormones (Winters et al., 2001) and 
growth factors (Platz et al., 1999; Tricoli et al., 1999; Winter et al., 2001) appear therefore to 
play a major role in explaining the observed racial differences in PCa rates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Age-Standardized prostate cancer incidence and mortality rates by world area. Source: 
GLOBOCAN 2008 (adapted from (Jemal et al., 2011)). 
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The number of cases has continuously increased over the past decades, partly due to 
the higher life expectancy. An additional factor is the western lifestyle, characterized by a 
highly caloric diet and lack of physical activity. 
In Europe, during the year 2008, the estimated number of newly diagnosed cases of 
PCa was 370,733, accounting for 21.8% of all cancers (Figure 2). In the same year, this 
cancer was also responsible for 9.4% of the cancer-related deaths (89,629 cases). In 
Portugal, PCa is the leading cancer among men, (Figure 2) with 5,140 estimated incident 
cases and lies on the third position of cancer-associated deaths (2,021 cases, 13.8%). 
 
      EUROPE, 2008 
                             Number of cancer cases (all ages) 
   Males total (1700,526) 
 
 
 
 
    
                                                                 PORTUGAL, 2008 
                                                                                                       Number of cancer cases (all ages) 
                                                               Males total (24,030) 
 
 
 
 
 
Figure 2 - Estimated cancer incident in Europe and Portugal (number of newly diagnosed cases and   
proportion of each cancer comparing with all types of cancer). Prostate cancer is the first most common 
cancer in both Europe and Portugal (adapted from GLOBOCAN, 2008)). 
 
1.2 Etiology and risk factors 
Many factors are thought to contribute to an increased risk of PCa, although 
consistent evidence is available for only a few of them, such as increasing age, African 
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ancestry, and a family history of the disease (Bostwick et al., 2004; Gronberg, 2003) (Table 
1). Age is one of the well-established risk factors, as the frequency of PCas rises very 
steeply with age, being exponential in men aged 65 or more (Eble et al., 2004). Ethnic origin 
seems also to play an important role in prostate carcinogenesis (Jemal et al., 2011). A family 
history of PCa that includes a first-degree relative is associated with a two-fold increased risk 
of developing the disease compared to the general population (Carter et al., 1992; Edwards 
and Eeles, 2004; Steinberg et al., 1990). Furthermore, epidemiologic evidence also supports 
a major contribution of environmental stresses, dietary factors (increased total fat intake, 
animal fat intake and red meat) and lifestyle-related factors, including obesity to the makeup 
of this disease. Further, there is some evidence that occupational exposures of firefighters 
(toxic combustion products) moderately increase risk (Nelson et al., 2003). The risk of PCa 
increases whenever Asian individuals immigrate to North America – once more implicating 
both the environment and lifestyle-related factors in causing PCa in the United States. 
 
Table 1 - Proposed risk factors for Prostate Cancer (adapted from (Gronberg, 2003)) 
     AR indicates androgen receptor. 
 
2. Prostate Cancer Anatomy and Mechanisms of Disease 
 
2.1. Anatomy and histology 
Prostate is an accessory gland of the male reproductive system. It is a walnut-sized 
gland that lies just below the urinary bladder and surrounds the upper part of the urethra. Its 
primary function is to secrete a slightly alkaline fluid (that forms part of the seminal fluid) into 
the urethra at the time of ejaculation, which helps to nourish and protect the sperm cells 
(Marandola et al., 2004). At the histological level, the prostatic pseudostratified epithelium is 
subdivided in four types of cells: luminal, basal, transient (an intermediate between the 
previous two) (Isaacs and Coffey, 1989), and neuroendocrine cells (Foster et al., 2002; 
Hudson, 2004; Peehl, 2005; Shappell et al., 2004; van Leenders and Schalken, 2003). In 
general terms, the luminal epithelial cells, forming a continuous layer of polarized columnar 
cells, are responsible for the physiological secretions of the prostatic gland. The basal cells 
Established Possible Uncertain 
Age 
Ethnic origin 
Family history 
Lycopene 
Zinc 
Selenium 
AR polymorphisms 
Vitamin D polymorphisms 
Dietary fat 
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are much lesser and rest in the basement membrane adjacent to the secretory cells and their 
absence is a helpful marker of PCa. Finally, neuroendocrine cells are thought to be involved 
in the regulation of prostatic secretory activity and cell growth (Joshua et al., 2008). The 
classic work of McNeal (1969, 1981, 1988) defined the human prostate as having a zonal 
architecture, corresponding to three anatomical zones: the central, the peripheral and the 
transitional zone (Timms, 2008) (McNeal, 1969, 1981, 1988) (Figure 3). Interestingly the 
transitional zone (TZ) is more prone to develop benign prostatic hyperplasia (BPH), a 
nonmalignant condition of older men. On the other hand, most prostate carcinomas occur in 
the peripheral zone (PZ) (Figure 3) (De Marzo et al., 2007; Shen and Abate-Shen, 2010). 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
Figure 3 -  A) Sagital view of prostate gland that specifically illustrates the three major anatomical zones 
of prostate (adapted from (Cohen et al., 2008)). B) Zonal predisposition to prostate disease. The major part of 
cancer lesions occur in the peripheral zone, fewer occur in the transitional zone and almost none occur in the 
central zone (adapted from (De Marzo et al., 2007)). 
  
2.2. Percursor and malignant prostate lesions 
The accumulation of multiple somatic genome alterations rather than any individual 
genetic lesion characterizes the different stages of prostate carcinogenesis (Figure 5). 
Whereas somatic genome alterations are likely to occur in a stochastic fashion rather than in 
A) 
B) 
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a stepwise manner, certain events are known to occur at particular stages of the prostate 
disease progression (Gonzalgo and Isaacs, 2003). 
Following the contemporary model of PCa progression suggested by Gonzalgo and 
Isaacs (2003) (Figure 4), there are some factors, including genetic predisposition, oxidative 
damage and inflammatory changes, associated with earliest steps of PCa development.  
 
 
 
 
 
 
 
 
 
Figure 4 - The Molecular Pathogenesis of Prostate Cancer (adapted from (Gonzalgo and Isaacs, 2003)). 
 
In more than 90% of PCa cases, the absence of Glutathione S-transferase pi 1 
(GSTP1) in PCa cells, by aberrant promoter hypermethylation of the CpG island sequences, 
may increase the likelihood for neoplastic transformation (Gonzalgo and Isaacs, 2003; Lin et 
al., 2001). On the other hand, the same absence of GSTP1 is also characteristic of prostatic 
intraepithelial neoplasia (PIN) lesions (Brooks et al., 1998). Although cells carrying 
inactivated GSTP1 alleles tend to accumulate during PCa progression, GSTP1 does not 
appear to act as a TSG (Lin et al., 2001). Instead, GSTP1 probably serves as a “caretaker” 
gene defending prostate cells against genomic damage mediated by carcinogens like 2-
amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP), present in well-done or charred 
meats, or even various oxidants, found at sites of inflammation (Stuart et al., 2000); (Nelson 
et al., 2001; Shirai et al., 1997). Other alterations like chromosomal loss and telomere 
shortening may also contribute to genetic instability and progression to invasive disease. 
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Further methylation changes, loss of TSG function and additional mutational events are 
associated with metastatic and androgen-independent disease (Gonzalgo and Isaacs, 2003). 
Adult males can experience two main types of prostatic disease: BPH and PCa. The 
former involves the nonmalignant proliferation of epithelial and stromal prostatic cells 
(Roehrborn, 2008) and is persistently under androgens stimulation (Hayward et al., 1997). 
BPH progresses in the TZ of prostate gland, around the urethra, and the pressure exerted 
can lead to urinary tract obstruction, causing consequently lower urinary symptoms. This is 
the most common urological disease in men, beginning in the third decade of life and 
affecting over half of the men aged more than 50 years and 90% of men aged more than 80 
years (Alcaraz et al., 2009). This pathology is often accompanied by an increase of serum 
PSA levels, however, in the vast majority of the cases, is not considered a pre-neoplastic 
lesion.  
The most well studied premalignant lesion in the prostate is PIN (Ramon and Denis, 
2007). It consists in the development of a variable degree of cytologic atypia in the epithelium 
lining the ducts and acini, being confined to the glands. At the histologic level, PIN is 
generally characterized by the appearance of luminal epithelial hyperplasia, reduction in 
basal cells, enlargement of nuclei and nucleoli, along with cytoplasmic hyperchromasia, and 
nuclear atypia (Bostwick, 1989; Shappell et al., 2004). Furthermore, two grades of this lesion 
spectrum (PIN) have been identified: low-grade PIN (LGPIN) and high-grade PIN (HGPIN). 
The latter is currently considered the only premalignant to PCa on the basis of pathological 
(Qian et al., 1997), epidemiological (Sakr et al., 1994; Sakr et al., 1993) and cytogenetic 
(Beheshti et al., 2002) evidence. In addition, HGPIN lesions generally display marked 
elevation of cellular proliferation markers (Bostwick, 1989; Shappell et al., 2004). Moreover, 
and based on recent data, the majority of the expression alterations that occur in the 
progression to PCa, take place in the transition from benign epithelium to HGPIN, rather than 
from HGPIN to PCa (Tomlins et al., 2007b). HGPIN is characterized by benign prostatic acini 
and ducts, lined up by cytological atypical cells (Bostwick et al., 2004) and its incidence 
increases with age (Eble et al., 2004). Bostwick and Quian subdivided HGPIN lesions into at 
least four different architectural patterns, which have no prognostic significance, ie, tuffed, 
micropapillary, flat and cribiform (Bostwick et al., 2004). Still, the volume of HGPIN has a 
positively correlation with tumor stage and Gleason grade, (Qian et al., 1997) as well as the 
risk of subsequent PCa (Bishara et al., 2004; Kronz et al., 2001). On the other hand, LGPIN 
alone is not associated with an increased risk for detection of carcinoma. 
An alternative, possibly earlier, of PCa is proliferative inflammatory atrophy (PIA), 
which displays foci of atrophic lesions occurring in association with inflammation. Regions of 
PIA are also often located in proximity with PIN and adenocarcinoma, and thus PIA has also 
been proposed to represent a precursor lesion in PCa (De Marzo et al., 1999; De Marzo et 
 10 
 
al., 2003). Although linking PIA to PCa is suggestive, this evidence is not as convincing as 
HGPIN (Joshua et al., 2008). 
Finally, prostate adenocarcinoma, which accounts for over 95% of all malignancies of 
the prostate (DeVita, 2008), is an aged-related disease, initially androgen-dependent, with a 
highly heterogeneous nature both in terms of pathology and clinical presentation, ranging 
from indolent, clinically silent,  to highly aggressive and lethal tumors (Boyd et al., 2012; 
Cassidy et al., 2010). Prostate adenocarcinoma is a multifocal and high heterogenic disease, 
with multiple pathways to the malignant phenotype and, as already described, usually 
located in the PZ of the prostate, as HGPIN lesions are (De Marzo et al., 2007; DeVita, 
2008). 
 
2.3. Natural history of prostate cancer 
  
2.3.1 Latent and clinical cancer 
Prostate cancers, being so heterogeneous, display a range of clinical behavior, from 
slow-growing tumor of no clinical significance to aggressively metastatic and lethal disease 
(Figure 5) (Boyd et al., 2012).  
 Figure 5 - Human prostate progression pathway. Each stage of disease progression is accompanied by 
molecular processes that are considered to be significant in each stage (adapted from (Shen and Abate-Shen, 
2010)). 
 
Moreover, the adjective “multifocal” is also very adequate to PCa, as primary tumors 
often contain multiple independent histologic foci of cancer that are often genetically distinct 
(Aihara et al., 1994; Bostwick et al., 1998; Cheng et al., 1998; Clark et al., 2008; Macintosh 
et al., 1998; Mehra et al., 2007). On the other hand, and contrarily to what has been stated 
above, despite the phenotypic heterogeneity of metastatic PCa (Shah et al., 2004), both 
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molecular and cytogenetic analyses show that metastases in the same patient are clonally 
related, suggesting that advanced PCa is monoclonal (Liu et al., 2009; Mehra et al., 2008). 
These evidences indicate that metastatic PCa may arise from the selective advantage of 
individual clones during cancer progression. However, Shen and Abate-Shen consider that 
this process of clonal evolution may also result from the androgen-deprivation therapeutic 
option, which may differentially target cells of varying malignant potential (Shen and Abate-
Shen, 2010). 
Although PCa is an elderly disease, studies of prostate specimens from healthy men 
in their 20s and 40s show the presence of multiple histologic foci of cancer (Sakr et al., 1994; 
Shiraishi et al., 1994; Yatani et al., 1989), conducting to the conclusion that cancer initiation 
has already taken place at a relatively early age. Thus, the prostate gland is a site of multiple 
neoplastic transformation events, many of which give rise only to latent PCa and not 
necessarily progress to clinically detectable disease. Therefore it is suspected that clinical 
PCa has a different “switch on” program than latent disease, or even may remain under 
active suppression sufficient to maintain these latent foci in a subclinical state (Shen and 
Abate-Shen, 2010) 
2.4. Molecular subtypes of prostate cancer 
Unlike other epithelial tumors, such as breast cancer, PCa lacks distinguishable 
histopathological subtypes that differ in their prognosis or even treatment response. It is 
known that the majority of PCas are acinar adenocarcinomas that express the androgen 
receptor (AR), while other categories of PCa, like ductal adenocarcinoma, mucinous 
carcinoma, and signet ring carcinoma are extremely rare (Grignon, 2004). 
However, a report from Taylor et al support the idea that oncogenomic pathway 
analyses, which integrate analyses of gene expression, copy number alterations (CNAs), and 
exon resequencing, may provide a unified approach for distinguishing PCa subtypes and 
therefore stratifying patient outcome (Taylor et al., 2010). Furthermore, Lapointe et al, 
crossing genomic data at the level of CNAs obtained from array comparative genomic 
hybridization (CGH) with gene expression data profiling 55 primary tumors and 9 lymph node 
metastasis, defined three subtypes of prostate carcinomas. Subtype-1 was mainly 
characterized by loss of 5q21 and 6q15; subtype-2 by TMPRSS2-ERG rearrangements and 
loss of 8p21 (NKX3.1) and subtype-3 by loss of 10q23 (PTEN) and gain of 8q24 (MYC). This 
profile was similar to that obtained for lymph node metastasis. Moreover, and regarding the 
patient outcome, subtype-1 was linked to clinically favorable behavior, and the other two 
(subtype-2 and -3) were linked with more aggressive disease (Lapointe et al., 2007).  
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2.5. Metastasis 
As already stated, if PCa metastasizes, it undoubtedly goes to bone, giving rise to 
osteoblastic, rather than osteolytic lesions (Bubendorf et al., 2000; Logothetis and Lin, 2005), 
although the typical sites of secondary metastasis for PCa are lung, liver and pleura (Shen 
and Abate-Shen, 2010). 
However, the mechanism by which the disseminated tumor cells form metastasis at 
distant regions of the body remains unclear, as well as the molecular factors that promote 
metastasis of PCa to the bone (Shen and Abate-Shen, 2010). 
 
3. Processes that Promote Prostate Carcinogenesis 
Regarding all the risk factors, already described, for PCa, the single most significant 
is advanced age. While men who are younger than 40 have 1 in 10.000 chance of 
developing PCa, this risk increases to 1 in 7 by the age of 60 (American Cancer Society: 
Cancer Facts and Figures 2012, 2013). Since different populations rate considerably 
different incidences (Jemal et al., 2011), PCa is not simply a by-product of aging. Therefore, 
the relationship between PCa and advanced age likely reflects the interplay of 
environmental, physiological and molecular influences with normal consequences of aging 
that presumably exacerbate the effects of these influences (Shen and Abate-Shen, 2010). 
Thus, various studies have described gene expression changes linked with aging, including 
those involved in inflammation and oxidative stress (Bavik et al., 2006; Begley et al., 2005; 
Bethel et al., 2009) 
 
3.1. Inflammation 
Epidemiological, pathological and molecular evidence have emphasized the idea that 
chronic inflammation is causally associated with prostate carcinogenesis (Bardia et al., 2009; 
Haverkamp et al., 2008; Klein and Silverman, 2008). Generally, the cause of prostate 
inflammation is unclear. However, the initial inciting event could be explained through various 
potential sources, including direct infection, urine reflux promoting both chemical and 
physical trauma, dietary factors, estrogens, or a combination of two or more of these factors 
(Figure 6) (Shen and Abate-Shen, 2010). Consequently, any of these factors could easily 
lead to a break of immune tolerance and the development of an autoimmune response to the 
prostate (De Marzo et al., 2007). 
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Figure 6 - Possible causes of prostate inflammation. a) Infection. The figure illustrates two cells infected either 
by bacteria or viruses. b) Hormones. Estrogenic exposures in the prostate. c) Physical trauma. The figure shows 
a corpora amylacea within a prostatic acinus. d) Urine reflux. e) Dietary habits (adapted from (De Marzo et al., 
2007)). 
 
Regarding the infectious agents, a chronic bacterial prostatitis is a rare recurring 
infection in which pathogenic bacteria are cultured from prostatic fluid. Furthermore, a 
potential role for bacterial infection in prostate carcinogenesis has been suggested when 
multiple bacterial species where identified in most prostatectomy samples examined (Sfanos 
et al., 2008). Some viruses (like human papillomavirus (HPV), human herpes simplex virus 
type 2 (HSV2), cytomegalovirus (CMV) and human herpes type 8 (HHV8)), mycobacteria 
and parasites can also infect and induce an inflammatory response in the prostate. Another 
factor related with prostate inflammation is urine reflux, ie, urine that travels up back towards 
the bladder (“retrograde” movement), that can penetrate the ducts and acini of the prostate 
gland. Crystalline uric acid, a particularly intriguing compound in this regard, directly interacts 
with a receptor that is part of a molecular pathway within innate immune cells that can 
potently stimulate inflammation. On the other hand, physical trauma is induced by the trauma 
of the prostate on a microscopic level by the corpora amylacea (Figure 6). Once corpora 
amylacea is within a prostatic acinus, its edges appear to be eroding the epithelium, resulting 
in an increased expression of the stress enzyme cyclooxygenase 2 (PTGS2), as it could be 
seen in the figure above. Taking into account the dietary habits, like PhIP, present in charred 
meats, can reach the prostate through the bloodstream or by urine reflux and cause DNA 
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damage and mutations, thus resulting in an influx of inflammatory cells (Shen and Abate-
Shen, 2010). Moreover, this potent heterocyclic amine (PhIP) promotes prostatic hyperplasia 
and PIN in rodents (Borowsky et al., 2006; Elkahwaji et al., 2009; Elkahwaji et al., 2007; 
Khalili et al., 2010; Nakai et al., 2007). As abovementioned, one of the well-studied genes 
responsible for prostate protection against carcinogens such as PhIP is GSTP1. 
Notably, regions of focal atrophic prostate epithelium can often be identified in older 
men, frequently associated with an inflammatory response. Furthermore, such regions 
usually display increased epithelial proliferation, and have been termed PIA (De Marzo et al., 
1999). Another potential “promoters” of an inflammatory response in the prostate are 
hormonal perturbations, including estrogen exposure at crucial development junctures that 
can result in prostate architectural modifications (De Marzo et al., 2007). 
 
3.2. Oxidative stress and DNA damage 
Oxidative stress and its cumulative impact on DNA damage has been suggested as 
one of the major aging-associated influences on prostate carcinogenesis, by several lines of 
evidence (DeWeese et al., 2001; Khandrika et al., 2009; Minelli et al., 2009). The constant 
imbalance of reactive oxygen species (ROS) and detoxifying enzymes, which control cellular 
levels of ROS, originates the oxidative stress that, in turn, leads to cumulative damage of 
lipids, proteins and DNA. Evidence linking oxidative stress and PCa initiation include 
correlative studies showing that major antioxidant enzymes are reduced in human PIN and 
PCa (Bostwick et al., 2000).Thus prostate gland appears to be very vulnerable to oxidative 
stress, perhaps as a product of the interplay of inflammation, hormonal deregulation, diet, 
and/or epigenetic alterations, such GSTP1 silencing. Furthermore, since the tumor 
suppressor NKX3.1 is frequently down-regulated in the onset of the disease, its inactivation 
may also contribute to the marked vulnerability of prostate to oxidative stress, as well as its 
damage to DNA, linked with cancer initiation (Shen and Abate-Shen, 2010). 
 
4. Androgens in Prostate Cancer 
Circulating androgens are essential for normal prostate development, as well as the 
onset of PCa through their interactions with the AR. Prostate cancer typically initiates as an 
androgen-sensitive lesion, but frequently develops into an androgen-insensitive status, while 
progressing to a more advanced stage (Figure 7). As it is illustrated in the figure below, 
normal prostate gland aging eventually leads to BPH in adult males. On the other hand, 
malignant development of the prostate may arise from PIN which, in turn, may remain as a 
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clinically and histologically dormant lesion, progress into organ-confined or locally invasive 
tumor, or finally evolve into hormone-refractory or metastatic disease (Koochekpour, 2011). 
 
 
 
 
 
 
 
 
 
 
Figure 7 - Prostate cancer development and progression through a multistep fashion (adapted from 
(Koochekpour, 2011)). 
 
 
Androgenic hormones are widely believed to regulate proliferation, apoptosis, 
angiogenesis, metastasis and differentiation (Imamoto et al., 2008). Testosterone and 
dihydrotestosterone (DHT) are the two main androgens in adult men. While testosterone, 
synthesized by the testis, is the major male circulating androgen, DHT is the principal 
androgen in tissues (such as prostate and skin). The latter arises from the conversion of 
testosterone through the action of the 5α-reductase enzyme and becomes about twice as 
potent as testosterone at stimulating prostate growth (Wright et al., 1996). It has been clear, 
since the mid 20th century, that DHT and not testosterone is the primary androgen 
responsible for the AR  mediated growth of normal and malignant prostate tissue (Tindall and 
Rittmaster, 2008). In the unbound state, AR is associated, in the cytoplasm, to heat shock 
proteins (Figure 8). Once bound to the AR, DHT causes heat shock protein dissociation, 
allowing AR translocation into the nucleus. Here AR binds androgen responsive elements 
(AREs) as a dimer in the promoter and enhancer regions of target genes. Lastly, the AR 
recruitment of coactivator proteins (Co) to these multiprotein complex enables target gene 
transcription in a regulated level (Tindall and Rittmaster, 2008). 
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Figure 8 - AR signaling pathway in prostate. In androgen responsive target cells, testosterone (T) is converted 
into DHT by 5αR enzymes. DHT binds to AR, causing heat shock protein dissociation, allowing DHT-AR complex 
translocation to the nucleus, where it binds to AREs. Finally, the recruitment of coactivator proteins (Co) enables 
transcriptional activation of target genes (adapted from (Tindall and Rittmaster, 2008)).                            
 
 
4.1. Progression to an androgen-independent status 
Early metastatic PCa is usually treated with androgen ablation, antiandrogens, or a 
combination of the two, which leads to a significant reduction of androgen-responsive cancer 
cells (Eisenberger et al., 1998; Koochekpour, 2011; Laufer et al., 2000). Despite an initial 
and clinically satisfactory response, manifested by rapid cellular apoptosis and evolution to 
the regressed state, to androgen-deprivation via chemical and surgical castration, 
progression is inevitable, due to the emergence of androgen-independent cancer cells. The 
tumor becomes hormone-refractory and more aggressive in the later stages, leading to a 
poor prognosis, incurable disease, and death (Kruglyak, 1999).  
Both PCa and progression to an androgen-independent status are dependent on AR 
expression and function. Its function is quite often heterogeneous, perhaps reflecting an 
underlying genomic instability (Boyd et al., 2012). Moreover, Zegarra-Moro et al suggested 
that receptors can drive the proliferation of androgen-independent cells even in the absence 
of androgens (Zegarra-Moro et al., 2002). 
Germline mutations in the AR gene are rarely identified in PCa patients, although 
polymorphisms that alter the response to androgens are frequently observed (Boyd et al., 
2012). One example of this is the fact that the length of the human AR polymorphic 
trinucleotide CAG tract, mapping to exon 1 of the AR gene, determines androgen sensitivity 
in vivo and short CAG repeat length has been associated with increased AR transactivation 
(Beilin et al., 2000; Mhatre et al., 1993; Simanainen et al., 2011). Regarding the prevalence 
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of short CAG repeats, it is greater in White men than in Asian men, being the black males the 
ones that are more prone to carry particularly short repeats (Kumar et al., 2011). It is 
noteworthy that ethnicity-based differences in mean AR CAG tract length correlate with 
ethnicity-based variations in both incidence and mortality (Buchanan et al., 2001; Hsing et 
al., 2000). Nevertheless, despite intensive research, the association between CAG repeat 
length and PCa risk remains unclear (Gu et al., 2012). 
 
5. Prostate Cancer Diagnosis 
A major challenge for urologists relates to the initial diagnosis and prognosis of PCa. 
The main diagnostic tools used to look for evidence of PCa include serum concentration of 
PSA, digital rectal examination (DRE) and transrectal ultrasound-guided biopsies (TRUS) 
(Smith et al, 2007). According to the European Association of Urology (EAU) guidelines for 
the diagnosis of PCa, this disease could be indicated by an abnormal DRE result or elevated 
serum PSA level (Heidenreich et al., 2011).  
 
5.1. PSA (Prostate Specific Antigen) 
Although widely accepted as a prostate tumor marker, PSA has turned out to be 
organ-specific but not PCa specific (Hessels et al., 2004). PSA is a serine protease produced 
by epithelial cells lining the prostatic ducts and is secreted directly into the prostatic ductal 
system (Figure 9). 
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 Figure 9 - Schematic illustration of PSA synthesis in epithelial cells and its secretion into prostatic ducts.   
 As PSA is a serine protease its normal mode of existence in the serum is in a complex with -1-anti- chymotrypsin 
(ACT) and -2-macroglobulin (AMG). Only a small percentage of PSA found in the serum is free (adapted from 
www.mens-hormonal-health.com). 
 
The main function of PSA is to liquefy the semen (Eble et al., 2004). Generally the 
normal PSA serum levels are <4ng/mL (Catalona et al., 1991), however it could be “normally” 
increased in aged and African men. The PSA blood test has changed the landscape of PCa, 
since its dissemination more than 20 years ago, rising the incidence in a dramatically way 
and helping to shift the stage of disease to a much earlier and potentially curable stage 
(Catalona et al., 1991; Cooner et al., 1990). However, testing for the early detection of PCa 
based on these methods remains a source of uncertainty and controversy (Wolf et al., 2010). 
The principal aim of screening for PSA was the evidence that elevated PSA levels were 
associated with asymptomatic/occult PCa. 
Still having now a huge lack of definitive answers from randomized trials, the 
traditional level of 4ng/mL is a reasonable threshold (meaning the higher risk of PCa), but 
need to suffer further evaluation. The fact that there is no true PSA cutoff point, since PSA 
level screening produce false positive (lead men without disease to unnecessary additional 
testing) and false negatives, results suggested that clinicians consider individualized decision 
making when PSA levels fall in the intermediate range of 2,5ng/mL to 4ng/mL, namely for 
men at increased risk for PCa based on other risk factors apart from PSA (Wolf et al., 2010). 
Any pathological process that leads to a significant increase of prostatic epithelial 
cells (BPH or PCa) or, in turn, changes the normal organ architecture (prostatitis or PCa), 
allows an additional amount of PSA to escape the prostate and disseminate to the 
bloodstream. Any significant increase in PSA serum levels should necessarily indicate a 
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proper study of the patient, including the prostatic biopsy, if indicated, to confirm the 
presence of cancer. Concerning now at what age should the early detection start and what is 
the interval of PSA, this test is not necessary in men >75 years and a baseline PSA ≤ 
3ng/mL, because they comprise the very low-risk patients of dying from PCa (Carter et al., 
2008).  
PSA level is a continuous parameter since the higher the value, the more likely the 
existence of PCa. However, the results from a US prevention study have shown that many 
men, even with low levels of serum PSA are prone to develop PCa (Thompson et al., 2004). 
Several approaches of serum PSA value have been suggested in order to improve PSA 
specificity in the early detection of PCa, including PSA density; measurement of PSA 
velocity; age-specific PSA; levels of free/total PSA and PSA molecular forms (Heidenreich et 
al., 2011). According to the published guidelines by the EAU, a free/total ratio < 20% and a 
PSA velocity > 0,75ng/mL/yr in combination with high PSA levels are the full criteria to dictate 
a high-risk man that must be submitted to a prostatic biopsy (Heidenreich et al., 2008). Given 
the lack of specificity and unclear benefit of PSA testing, alternative markers and methods 
are required to avoid the overdiagnosis and overtreatment of patients with elevated levels of 
this prostate-specific antigen (Boyd et al., 2012). 
 
5.2. DRE (Digital Rectal Evaluation) 
This was the first and sole ancillary-tool of screening men for PCa before the PSA 
testing era. Prostate cancer could be detected by a suspect DRE alone, irrespective of the 
PSA level, in only about 18% of all patients (Carvalhal et al., 1999), but it does not have 
enough sensitivity to detect the small-volume tumors that are most amenable to cure. About 
60% of the PCas detected by this method have already extended beyond the prostatic gland, 
being therefore at an advanced or even metastatic stage (Epstein, 2010). Taking into 
account the above reasons, it is important to have an optimized diagnostic strategy using a 
combination of DRE and serum PSA testing in order to increase the yield of PCa diagnosis. 
 
5.3. (TRUS) Transrectal Ultrasound-Guided Core Biopsy 
Apart from other ancillary-tools for the detection of PCa, it is known that the diagnosis 
of this pathology is based on histological examination (van der Kwast et al., 2003). 
Therefore, TRUS-guided biopsy has become the recommended method in cases of 
suspected PCa, since it is the standard way to obtain material to histopathological 
examination of the prostatic gland (Hara et al., 2008; Takenaka et al., 2008). Recently, 
studies have shown that protocols used at first biopsy should include be 10 to 12 cores, in 
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order to increase the PCa detection rate (Eichler et al., 2006; Hara et al., 2008). Moreover, 
collecting more than 12 cores does not bring significantly more conclusive results (Eichler et 
al., 2006). 
Needle biopsies, unlike fine-needle aspiration (FNA), provide more specific 
information about tumor extent and sometimes about extra-prostatic extension and seminal 
vesicles invasion. So, it is of extreme importance that, before any treatment of localized  
PCa, the diagnosis should be confirmed by core biopsies (Eble et al., 2004). The main 
disadvantage of needle biopsies is the small size of the tissue available for histological and 
molecular cytogenetic analysis and the low tumor representativeness (difficulty of 
identification of few malignant glands among many benign glands) (Epstein, 1995). 
 
5.4. Prognostic factors 
 
5.4.1. Grading 
In 1966 Donald F. Gleason created a unique grading system for prostatic 
adenocarcinoma based on the architectural pattern of tumor growth, as well as on the extent 
of glandular differentiation (as seen under low-magnification) (Gleason and Mellinger, 1974; 
Mellinger et al., 1967). The Gleason grading comprises five histological grades of cancer on 
a scale from 1 (most differentiated) to 5 (poorly differentiated) (Figure 10; Table 2). 
 
 
 
 
 
 
 
 
 
 
Figure 10 - Updated Gleason score diagram (adapted from (Epstein, 2010)) 
Pattern 1: Closely packed small, uniform glands. 
Pattern 2: More stroma between the glands. It may 
minimally invade non-neoplastic tissue. 
Pattern 3: Marked irregular size glands with angular 
shape and infiltrative margins. 
Pattern 5: Only ocasional gland formation. It is 
associated with poor prognosis. 
Pattern 4: Fused, cribiform or poorly defined glands. 
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Grade is one of the strongest predictors of biological behavior (invasiveness and 
metastatic potential), thus having an important clinical significance to help therapeutic 
decision making. More than 50% of prostate tumors are characterized by heterogeneity with 
regard to pathologic development, molecular abnormalities, and clinical outcome (Clark and 
Cooper, 2009). So, the recognition of this heterogeneity, by Gleason, led to the incorporation 
of the two dominant and most common grades into his system, establishing the Gleason 
score (GS). This score reflects better the prognosis of the patient and consists in the addition 
of both primary (the most predominant) and secondary patterns (the second most frequent). 
In consequence, the GS system comprises four stages of differentiation that range from 2 to 
10 (Table 2) (Gleason and Mellinger, 1974). Regarding the prognostic significance (Table 2), 
a tumor harboring a GS 2 to 6 has better prognosis as it is well to moderately-well 
differentiated, a Gleason 7 tumor is moderately to poorly differentiated associated with an 
intermediate prognosis, and a Gleason 8 to 10 tumor is poorly differentiated and is 
associated with a worse prognosis (Humphrey, 2004). Therefore, the higher the score the 
more aggressive the tumor is and the higher the chance for the patient to have a poor 
outcome (Humphrey, 2004). 
 
Table 2 - Relationship between Gleason Score and prognostic significance (adapted from (Humphrey, 
2004)). 
 
5.4.2. Staging  
Staging is the grouping of diseases into broad categories based on the extent of 
disease, being helpful for the prediction of prognosis, as well as to delineate the more 
appropriate therapeutic strategy. Current clinical and pathological staging of early PCa relies 
on the palpability of the tumor by DRE and PSA measurement. Therefore, the most widely 
used staging system for PCa is the TNM (Tumor-Node-Metastasis) proposed by the 
American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control 
(UICC) (Table 3). This system takes into account the extent of the primary tumor (T), the 
involvement of regional lymph node (N) and the presence or absence of metastasis at distant 
sites of the body (M). Stage could also be reported based on the clinical evidence obtained 
before the treatment, by using minimally invasive methodologies (clinical stage), or through 
Gleason score General terminology 
2 - 4 (1+1, 1+2, 2+2) 
5 - 6 (2+3, 3+3) 
7 (3+4, 4+3, 2+5) 
8 – 10 (4+4, 4+5, 5+5) 
Well differentiated 
Intermediately differentiated 
Moderately differentiated 
Poorly differentiated 
A 
 22 
 
pathological findings after surgical remove of the prostate gland (pathological stage). The 
latter could estimate the prognosis (Edge and Compton, 2010). It is relevant to distinguish 
intracapsular tumors (stages T1, T2) from extracapsular tumors (T3a, T3b), because it has a 
strong impact in the therapeutic decision, since only organ confined tumors have a potentially 
curative treatment (Noldus et al., 2000). 
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Table 3 - Overview of the TNM / pTNM staging system for PCa (adapted from (Edge and Compton, 2010)). 
*There is no pathologic T1 classification 
  
Primary Tumor (T) 
   Tx   Primary tumor cannot be assessed 
    T0  No evidence of primary tumor 
    T1  Clinically inapparent tumor not palpable or visible by imaging 
         T1a             Tumor incidental histologic finding in 5% or less of tissue resected 
         T1b Tumor incidental histologic finding in more than 5% of tissue resected 
         T1c Tumor identified by needle biopsy (e.g. because of elevated PSA) 
    T2  Tumor confined within prostate 
         T2a Tumor involves one half of one lobe or less 
         T2b Tumor involves more than half of one lobe, but not both lobes 
         T2c Tumor involves both lobes 
    T3  Tumor extends beyond the prostate 
         T3a Extracapsular extension (unilateral or bilateral) 
         T3b Tumor invades seminal vesicle(s) 
         T4  Tumor is fixed or invades adjacent structures other than seminal vesicules such     
                         as external sphincter , rectum bladder, levator muscles, and/or pelvic wall 
Pathological (pT)* 
   pT2  Organ confined 
         pT2a Unilateral, involving one-half of one lobe or less 
         pT2b Unilateral, involving more than one-half of one lobe but not both lobes 
         pT2c Bilateral disease 
   pT3  Extraprostatic extension 
         pT3a Extraprostatic extension 
         pT3b Seminal vesicle invasion 
   pT4  Invasion of bladder, rectum 
Regional Lymph nodes (N) 
   Nx  Regional lymph nodes cannot be assessed 
   N0  No regional lymph node metastasis 
   N1  Regional lymph node metasatsis 
Pahologic (pN) 
   pNx  Regional nodes not sampled 
   pN0  No positive regional nodes 
   pN1  Metastases in regional node(s) 
Distant metastasis (M) 
   M0  No distant metástases 
   M1  Distant metastasis 
        M1a Non-regional lymph node(s) 
        M1b Bone(s) 
        M1c Other site(s) with or without bone disease 
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6. Treatment Options for Prostate Cancer 
The aim of treatment is to “cure” the cancer or to prolong survival in patients with 
advanced disease, while preserving the highest possible quality of life in both the long and 
short term. There are many treatment options depending on age, stage and grade of cancer, 
PSA level, as well as patient comorbidity and personal preferences (Siegel et al., 2012). 
According to the evaluation of these features, several therapeutic options are available for 
PCa patients: active surveillance, radical prostatectomy, radiotherapy, hormone therapy and 
chemotherapy. Surgery, external beam radiation or brachytherapy may be used to treat early 
stage disease. More advanced disease is usually treated with androgen deprivation therapy, 
chemo and radiation therapy or a combination of them (American Cancer Society: Cancer 
Facts and Figures 2012, 2013). 
  
6.1. Active surveillance 
Active surveillance (AS) does not mean the same as watchful waiting (WW) and the 
two treatment options must be differentiated. The latter is a reasonable and commonly 
recommended approach, with noncurative intent in patients that are unlikely to benefit from 
aggressive local therapy (Bhatnagar and Kaplan, 2005). The former must be seen as a 
suitable therapy for those who also be offered a curative approach (Heidenreich et al., 2011). 
This treatment option aims to reduce the ratio of overtreatment in patients with clinically 
localized low-risk PCa based on early data (Albertsen et al., 1998; Chodak et al., 1994) 
revealing that men with well-differentiated PCa have a survival rate of 80-90%. Some data 
has recently demonstrated that men with a low-risk PCa and a life expectancy > 10 years are 
good candidates for AS, whereas only 30% of men will required delayed radical intervention 
(Klotz et al., 2010).  
In conclusion, those men with a clinically localized PCa (T1-T2), a GS ≤ 6; three or 
fewer biopsies involved with cancer, ≤ 50% of each biopsy involved with cancer and a PSA = 
10ng/mL are potential AS patients. 
  
6.2. Radical prostatectomy 
Surgical removal of prostatic gland and seminal vesicles is the only potential curative 
treatment for patients with normal erectile function, clinical localized PCa (Aus et al., 2005). It 
is recommended in men aged younger than 65 years (about 57%), with a life expectancy ≥ 
10 years, low comorbidities, with moderately and poorly differentiated tumors and clinical 
stage T1 - T2 disease (Aus et al., 2005; Bhatnagar and Kaplan, 2005). The risk of lymph 
node involvement is low in men with low-risk PCa and <50% positive biopsy cores 
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(Heidenreich et al., 2011). However, an extended pelvic lymphadenectomy should always be 
performed in those men with intermediate and high-risk PCa (Briganti et al., 2006).  
 
6.3. Radiotherapy 
In Europe, the 1990s saw the introduction of three-dimensional conformal 
radiotherapy (3D-CRT), the gold standard option for men with advanced localized PCa (Aus 
et al., 2005) that are no longer candidates to undergo radical prostatectomy. This fact is 
mainly due to advanced age, thus having a high-risk of not achieving surgical complete 
clearance or patient preference. At the onset of the third millennium, intensity modulated 
radiotherapy (IMRT), an optimized and image-guided form of 3D-CRT, is becoming more 
widely used (Aus et al., 2005; Heidenreich et al., 2011).  
Radiotherapy can be effectively delivered by both external beam therapy and 
brachytherapy. The former uses an external dose-escalated irradiation scheme that offers 
the same long-term survival results and provides a quality of life at least as good as surgery 
(Fowler et al, 1996). The latter consists in the interstitial implantation of radioactive seeds in 
the prostate gland and is offered to patients that have a low-volume and low-grade prostate 
tumors (Heidenreich et al., 2011; Norderhaug et al., 2003). 
 
6.4. Hormonotherapy 
Early metastatic PCa may be controlled by hormone therapy, for long periods, 
through shrinking the size or limiting the growth of the cancer, thus helping to relieve the 
pain, since curative intent is no longer an option (American Cancer Society: Cancer Facts 
and Figures 2012, 2013). Nowadays, in human patients, available options for PCa treatment 
aim to inactivate the AR by androgen deprivation, through surgical (bilateral orchiectomy) or 
either chemical castration (luteinizing hormone release hormone (LHRH) agonists), blockade 
with antiandrogens such as flutamide, bicalutamide or even estrogens (Koochekpour, 2011; 
Shen and Abate-Shen, 2010). In fact, androgen-deprivation is the only reliable treatment 
approach for advanced PCa, being effective in about 80-90% of men in this stage of the 
disease (median-free survival of 12 to 33 months) (Denis and Murphy, 1993). As it had been 
shown by Huggins and colleagues in the 1940s, removal of testicular androgens by surgical 
or chemical castration will lead to regression of prostate tumors. However, androgen-
depletion is usually associated with the recurrence of PCa, as monitored by rising PSA 
levels, being this recurrent disease termed “castration-resistant” (Huggins and Hodges, 1941; 
Huggins and Hodges, 2002), which is sensitive to androgens and responsive to a 2º line of 
hormonal treatment. On the other hand, in hormone-resistant PCa (HRPC) chemotherapy 
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with docetaxel should be considered (Mottet et al., 2011). More recently, hormonal therapy 
has been offered as adjuvant therapy in combination with radical prostatectomy or 
radiotherapy, but only for the latter case it has shown improvement of survival in patients at 
this advanced stage of PCa. 
 
6.5. Chemotherapy 
Chemotherapy in PCa patients, including cytotoxic agents, is an active area of 
research. The most appropriate indication for chemotherapy is the clinical scenario of 
symptomatic metastases. In patients with skeletal metastases or a rapid PSA doubling time 
(DT) < 6 months, primary docetaxel should be considered (Mottet et al., 2011). Because all 
patients with castration-resistant PCa (CRPC) who received docetaxel-based chemotherapy 
progresses within 6-8 months, alternative treatments, including vinorelbine, mitoxantrone, or 
molecular-target therapy are under investigation and might be considered (de Bono et al., 
2010; Fizazi et al., 2010; Sternberg et al., 2009) 
 
7. The Prostate Cancer Genetics 
 
7.1. Epigenetic alterations 
Being a cause of changes in gene expression, epigenetic perturbations are believed 
to represent important contributing factors in prostate carcinogenesis, and may provide 
useful biomarkers for disease progression (Li et al., 2005; Nelson et al., 2009; Nelson et al., 
2007). These epigenetic mechanisms occur with advancing age in the prostate (Kwabi-Addo 
et al., 2007), early in prostate carcinogenesis (Yegnasubramanian et al., 2004), coordinately 
(Florl et al., 2004) and influence crucial processes in tumor formation. Although the cause of 
these epigenetic events remains unclear, some evidences suggest that these epigenetic 
regulatory mechanisms appear sensitive to external factors, including diet and oxidative 
stress, and consequently may act as interpreters of the effect of these environmental effects 
in prostate carcinogenesis (Aitchison et al., 2007; Herceg, 2007). 
There are three main interacting epigenetic phenomena: DNA methylation, histone 
modification and micro-RNAs (miRNAs). Regarding the first epigenetic phenomena, focal 
hypermethylation of critical genes has attracted most interest on deducing the pathogenesis 
of PCa (Joshua et al., 2008). DNA methylation has been implicated in silencing genes 
involved in diverse tumor processes, namely signal transduction, hormone response, cell 
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cycle control, and oxidative damage response, such as GSTP1 (Joshua et al., 2008; Li et al., 
2005; Shen and Abate-Shen, 2010). 
Histone modifications, such as acetylation and methylation, are other relevant 
epigenetic alterations. It is known that prostate tumors display global changes in chromatin 
modification coincident with cancer progression (Ke et al., 2009; Kondo et al., 2008). One 
prominent and key modification associated with prostate carcinogenesis is trimethylation of 
lysine 27 of histone H3 (H3K27-me3), mediated by the histone methyltransferase EZH2. This 
polycomb group gene EZH2 (Figure 5) (Shen and Abate-Shen, 2010) is a key oncogenic 
driver, being up-regulated in advanced disease, in some cases through amplification, and 
metastases, thus being associated with aggressive tumors (Bachmann et al., 2006) and 
worse prognosis (Saramaki et al., 2006; Varambally et al., 2002; Yu et al., 2007). Moreover, 
global changes in histone modifications are also associated with cellular senescence 
(Funayama and Ishikawa, 2007). 
Short (~22bp) non-coding RNAs (miRNAs) are known to regulate both normal 
processes of growth and development and pathogenic processes associated with cancer. 
Furthermore, several authors have performed expression profiling studies of human prostate 
tumors and xenografts, suggesting that the expression patterns of miRNAs may distinguish 
indolent from aggressive tumors (Ambs et al., 2008; Coppola et al., 2010; DeVere White et 
al., 2009; Ozen et al., 2008; Porkka et al., 2007), as well as have implicated specific mi-
RNAs in CRPC (Shi et al., 2007; Sun et al., 2009). 
 
7.2. Germline mutations and polymorphisms 
Several studies have shown a familial aggregation of PCa and this could be explained 
by the inheritance of gene mutations that cause this disease. Some PCa susceptibility loci 
were recently identified by microsatellite-based linkage studies (Table 4), including the 
hereditary prostate cancer 1 (HPC1) locus on 1q23-25 (harboring the RNASEL gene) 
(Carpten et al., 2002; Smith et al., 1996; Xu, 2000); the predisposing for cancer prostate 
(PCAP) locus on 1q42-43 (Berthon et al., 1998); the cancer prostate and brain (CAPB) locus 
on 1p36 (Gibbs et al., 1999); the HPC2 locus on 17p (which ELAC2 is the candidate allele) 
(Tavtigian et al., 2001); the HPC20 locus on 20q13 (Berry et al., 2000) and the HPCX locus 
on Xq27-28 (Xu et al., 1998). Last but not least, arises the identification of a new 
susceptibility region at 17q21 (harboring the BRCA1 gene) (Gillanders et al., 2004), 
discovered when the results of several linkage studies (Lange et al., 2003; Schleutker et al., 
2003; Wiklund et al., 2003; Xu et al., 2003; Xu et al., 2001) were reanalyzed as a combined 
dataset based on 426 families with hereditary PCa (Gillanders et al., 2004). Single nucleotide 
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polymorphism (SNP) based linkage analyses confirmed that chromosome 2, chromosome 6, 
region 8p22-23, and chromosome 12 harbor PCa susceptibility loci. A new candidate gene 
was identified by Xu et al – pannexin 1 (PANX1, also known as MSR1) mapping to 8p22-23 
(Xu et al., 2001). 
Recently, a new susceptibility gene, homeobox B13 HOXB13, for the locus 17q21-22 
was discovered by Ewing (Ewing et al., 2012), which harbors a rare mutation (G84E) that is 
associated with an increased risk of familial PCa (Boyd et al., 2012). HOXB13 is a homeobox 
transcription factor with a crucial role in normal prostate development. However, its function 
on prostate carcinogenesis is still controversial, since it has been implicated as both a TSG 
and an oncogene (Kim et al., 2010a; Kim et al., 2010b). 
 
 
Table 4 - Prostate cancer susceptibility loci discovered by linkage analysis. Nevertheless, some of these 
linkage loci HPC1, PCAP, and CAPB (chromosome 1) and the HPC2 (chromosome 2) revealed difficulty  to 
replicated with confidence (adapted from (Boyd et al., 2012)). 
 
 
  
With the development of SNP array technology and in order to identify common 
variants, at multiple loci, that have a moderate effect on PCa risk, a powerful tool has 
emerged -  genome-wide association study (GWAS) (Eeles et al., 2009; Gudmundsson et al., 
Chromosomal position Susceptibility locus Associated gene 
1p36 
1q23-25 
1q42-43 
2q23 
4q21 
5q31 
6p22 
7p21 
7q32.1 
8p22-23 
8q24 
9q34 
12p13-14 
16q23 
17p 
17q21-22 
17q21 
19q12-13.11 
20q13 
22q12.3-13.1 
Xq27-28 
CAPB 
HPC1 
PCAP 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
HPC2 
- 
- 
- 
HPC20 
- 
HPCX 
- 
RNASEL 
- 
- 
- 
- 
- 
- 
- 
MSR1 
- 
- 
- 
- 
ELAC2 
HOXB13 
BRCA1 
- 
- 
APOL3 
- 
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2009; Gudmundsson et al., 2007; Gudmundsson et al., 2008; Kader et al., 2009; Takata et 
al., 2010; Thomas et al., 2008). Study data from the first two PCa GWASs highlighted a 3.8 
Mb region on the 8q24 chromosome band, comprising the oncogene MYC (Amundadottir et 
al., 2006; Freedman et al., 2006). Consequently, at least nine SNP loci were shown to be 
independently associated with PCa risk, mapping to this chromosome region, in addition to 
29 predisposition SNP loci in other chromosomes (Ahn et al., 2011; Al Olama et al., 2009; 
Amundadottir et al., 2006; Gudmundsson et al., 2007; Kote-Jarai et al., 2011). Taking into 
account the later GWAS performed by Kote-Jarai and colleagues, that have identified seven 
new PCa susceptibility loci at 2p11, 3q23, 3q26, 5p12, 6p21, 12q13 and Xq12 (Kote-Jarai et 
al., 2011), in total nearly 50 PCa susceptibility loci have now been identified (Gudmundsson 
et al., 2008; Kote-Jarai et al., 2011; Thomas et al., 2008). 
. 
 
7.3. Somatic genetic alterations 
A central goal in cancer research is to identify genes that play a key role in cancer 
progression, either by being mutationally inactivated or downregulated, such as TSGs or 
caretakers/gatekeepers, or by being activated, such as oncogenes (Figure 11) (Table 5). 
8.  
Figure 11 - Human prostate cancer progression pathway. Each stage of disease progression is accompanied 
by gene/pathways that are considered to be important in each stage (adapted from (Shen and Abate-Shen, 
2010)). 
 
7.3.1 Negative regulators of carcinogenesis: tumor suppressor genes 
Among all the well-established TSGs in other neoplasias, only tumor protein p53 
(TP53) and phosphatase and tensin homologue (PTEN) have been shown to play a role in 
prostate carcinogenesis, where losses of 17p13 and 10q23, respectively, are indeed 
observed in advanced carcinomas. Mutations in the TP53 are present in a minority of primary 
tumors (10-20%) and may undergo clonal selection during the process of progression to 
metastatic PCa (20-30%) of advanced localized prostate tumors (Brooks et al., 1996; 
Grignon et al., 1997; Quinn et al., 2000; Stapleton et al., 1997). 
 PTEN encodes a phosphatase active against both proteins and lipid substrates. The 
mechanism by which PTEN might act as a TSG in the prostate may involve the inhibition of 
the phosphatidylinositol 3´-kinase-protein kinase B (PI3K-AKT) signaling pathway that is 
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essential for cell-cycle progression and cell survival, allowing normal cell death (Furnari et 
al., 1998; Li and Sun, 1998; Ramaswamy et al., 1999; Sun et al., 1999). 
 Furthermore, recent studies have investigated PTEN copy number, mutational 
status, and/or protein expression in primary and castration-resistant tumors using multiple 
experimental approaches (Schmitz et al., 2007; Sircar et al., 2009; Taylor et al., 2010; 
Verhagen et al., 2006). These studies, in consensus with previous reports, have concluded 
that PTEN undergoes copy number loss as an early event in prostate carcinogenesis (Figure 
11), and is correlated with progression to aggressive, castration-resistant disease (Shen and 
Abate-Shen, 2010). Moreover, mutations on PTEN gene are more common (30-60%) in 
metastatic samples than they are in primary tumors (5-27%) (Karan et al., 2003; Suzuki et 
al., 1998), being correlated with a high grade (GS) and stage (McMenamin et al., 1999). Low 
levels of PTEN activity may be retained in PCa – an observation that parallels the NK3 
homeobox 1 (NKX3.1) haploinsuficiency and the p27 cell regulator (Abate-Shen et al., 2008; 
Gao et al., 2004).  
Regarding the in vivo models, germline loss of PTEN in heterozygous mutants or 
conditional deletion in the prostate epithelium results in PIN and/or adenocarcinoma (Di 
Cristofano et al., 1998; Podsypanina et al., 1999; Trotman et al., 2003; Wang et al., 2003). 
Moreover, the inactivation of PTEN has been shown to cooperate with loss of function of the 
NKX3.1 homeobox gene, up regulation of MYC, or the TMPRSS2-ERG fusion (Carver et al., 
2009; Kim et al., 2009; Kim et al., 2002; King et al., 2009). 
On the other hand, further investigations of PTEN loss – together with perturbations 
of cell cycle regulators such as p27, p18 ink4c, and p14 arf (Bai et al., 2006; Chen et al., 2009; 
Di Cristofano et al., 2001) or components of key signaling pathways like RHEB, TSC2 and 
RICTOR (Guertin et al., 2009; Ma et al., 2005; Nardella et al., 2008) – have emphasized the 
relevance of haploinsuficiency in PCa context (Shen and Abate-Shen, 2010). Notably, PTEN 
reduction or loss in PCa actually predisposes to the emergence of CRPC (Mulholland et al., 
2006; Shen and Abate-Shen, 2007). While this may reflect the ability of PTEN to interact with 
androgen receptor (AR), the mechanistic details by which PTEN loss promotes castration-
resistance remains incompletely understood (Karan et al., 2003; Shen and Abate-Shen, 
2010).  
Another well-studied candidate in recurrently deleted genomic region is NKX3.1. No 
“gatekeeper” genes for the development of PCa, analogous to the adenomatous polyposis 
coli (APC) gene in colorectal cancer, have been identified (Kinzler and Vogelstein, 1997). 
NKX3.1, which maps to the 8p21 locus, encodes a homeobox gene that is likely to be 
essential for prostate development and is therefore a candidate gatekeeper gene (Bieberich 
et al., 1996; Sciavolino et al., 1997). Moreover, its relevance to prostatic carcinogenesis was 
originally described on the basis of loss of heterozygozity (LOH) of chromosome 8p21 in up 
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to 85% of HGPIN lesions and adenocarcinomas (Bethel et al., 2006; Emmert-Buck et al., 
1995; Haggman et al., 1997; Swalwell et al., 2002; Vocke et al., 1996). Notwithstanding, LOH 
of 8p21 progressively increases in frequency with cancer grade (Figure 11), but the 
remaining allele of NKX3.1 remains unmutated (Bethel et al., 2006; Ornstein et al., 2001; 
Vocke et al., 1996; Voeller et al., 1997). Furthermore, one study has reported NKX3.1 
deletion or loss of function in 20% of PIN lesions, 34% of androgen-independent PCas and in 
78% of PCa metastases, justifying why it has been correlated with disease progression 
(Bowen et al., 2000). Therefore, it has been concluded that there is an association between 
8p deletions and NKX3.1 expression in more advanced PCa, suggesting that genetic 
deletions may be more important in the progression of invasive disease whilst decrease 
NKX3.1 expression is more important in initial stages of the disease (Joshua et al., 2008). 
Once more regarding the expression of this gatekeeper gene in PCa, although early studies 
had suggested that NKX3.1 expression is completely lost in advanced cancers (Bowen et al., 
2000), recent analyses, using a highly sensitive antibody, indicate that low levels of NKX3.1 
expression can be demonstrated in nearly all PCas and metastases examined (Gurel et al., 
2010). Therefore, it appears to be a selection for reduction, but not loss, of NKX3.1 
expression during PCa progression. 
Moving to the functional studies, analyses of NKX3.1 in human tumor cells and 
genetically engineered mice have provided insights into its potential role in cancer initiation. 
When NKX3.1 was inactivated in mice, it resulted in a defective response to oxidative 
damage, while its expression in human PCa cell lines protects against DNA damage and is 
regulated by inflammation (Bowen and Gelmann, 2010; Markowski et al., 2008; Ouyang et 
al., 2005). NKX3.1 represents a haploinsuficiency TSG that behaves has a gatekeeper gene 
in prostate carcinogenesis initiation (Gelmann, 2003; Kim et al., 2002; Magee et al., 2003). 
Other TSGs with known somatic mutations in PCa are identified in the table below 
(Table 5) and particularly RB1, CDKN2A and TP53 are inactivated in hormone-refractory and 
metastatic tumors, suggesting a role of these genes in PCa progression. 
 
7.3.2 Elevated expression and gain of function: oncogenes 
Regarding the somatic “gain-of-function” alterations identified in PCa, the most 
frequent oncogenic changes belong to the category of amplifications, such as the 8q24 and 
Xq11 loci. These chromosome regions encompass putative target genes, such as MYC and 
AR, respectively, both well-known proto-oncogenes. 
The MYC (avian v-myc myelocytomatosis viral oncogene homolog) gene is a member 
of the basic Helix-loop-Helix Leucine Zipper (b-HLH-LZ) family of transcription factors that 
plays a role in cell-cycle progression, apoptosis and cellular transformation (Grandori et al., 
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2000; Lavigne et al., 1998). It is known that both overexpression and amplification of MYC 
are more prone to occur in recurrent and metastatic lesions than in primary tumors. In order 
to corroborate this fact, Jenkins et al, by using a Fluorescence In Situ (FISH) approach to 
detect MYC amplification and chromosomal abnormalities, have stated that amplification was 
identified in 21% of metastatic and in only 8% of carcinoma foci, but not in PIN foci (Jenkins 
et al., 1997). Similarly, Visakorpi and colleagues (1995) found gains of 8q more frequently in 
locally recurrent cancer, rather than in primary cancer (Visakorpi et al., 1995) and 
amplification of 8q was observed in 75% of lymph node metastases (Van Den Berg et al., 
1995). Moreover, Nupponen et al have demonstrated that the 8q24 gain was present in up to 
90% of advanced tumors (Nupponen et al., 1998), thus correlating with high histological 
grade (Jenkins et al., 1997). Later on, Ribeiro et al, have shown that 8q24 gain is an 
independent predictor of poor survival in PCa patients (Ribeiro et al., 2007). However, Gurel 
et al  (2008) have recently suggested a role for MYC overexpression in cancer initiation, as 
nuclear MYC protein is up-regulated in many PIN lesions and the majority of carcinomas in 
the absence of gene amplification (Gurel et al., 2008).  
These results may be consistent with the identification of a major susceptibility locus 
at 8q24 in several large-scale GWASs of PCa, as well as other epithelial cancers (Al Olama 
et al., 2009; Amundadottir et al., 2006; Freedman et al., 2006; Gudmundsson et al., 2009; 
Gudmundsson et al., 2007), but detailed analyses have not yet revealed any correlation 
between risk alleles and MYC RNA expression levels in prostate tumors samples, or even 
the presence of any non- protein-coding genes such as miRNAs (Pomerantz et al., 2009). 
Nonetheless, long-range regulatory elements for MYC have been recently identified in this 
region, arising de possibility that the risk alleles may disturb the regulation of MYC (Jia et al., 
2009; Sotelo et al., 2010). Regarding MYC regulation/ repression, another study conducted 
by Wang and colleagues has showed that the X-linked  forkhead box P3 gene  (FOXP3) 
encodes a winged helix transcription factor that represses MYC expression, being itself 
mutated in PCa (Wang et al., 2009). 
At the functional dimension, it was proved by Ellwood-Yen et al that transgenic mice 
expressing human MYC display rapid development of PIN, followed by progression to 
invasive adenocarcinoma despite having rare metastases (Ellwood-Yen et al., 2003). 
Interestingly, bioinformatic analyses have identified an expression signature characterized by 
down-regulation of NKX3.1 and up-regulation of PIM1, which is an oncogene known to 
collaborate with MYC in lymphomas (Ellwood-Yen et al., 2003). In consistence with these 
data, lentiviral coexpression of human MYC with mouse PIM1 in tissue recombinants results 
in cooperative formation of carcinomas with neuroendocrine differentiation (Wang et al., 
2010). Taking into account all these reports, it is suggested that both overexpression and 
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amplification of the MYC gene may play a role in the progression and evolution of prostate 
carcinoma. 
Another “gain-of-function” gene implicated in recurrence of PCa is AR, located in the 
Xq11 locus. Although somatic AR mutations are rarely detected in early stage disease, 
mutation or amplification is significantly increased in advanced androgen-independent 
tumors, thus suggesting a role of AR mutations in tumor progression (Feldman and Feldman, 
2001; Koivisto et al., 1997). About 20-30% of the castration-resistant PCas are AR mutated 
or amplified (Boyd et al., 2012). 
One question that persists is how can AR gene continue to drive the growth of 
androgen-depleted cells? Several mechanisms have been proposed and one possible 
explanation for this question is the occurrence of mutations in the receptor that cause its 
constitutional activation or, in turn, enable activation by other alternative ligands like steroids 
(Feldman and Feldman, 2001; Gregory et al., 2001; Linja et al., 2001). Over 70 different 
somatic missense AR mutations have been described, but only a few have been functionally 
studied (Gottlieb et al., 2004). 
 
Table 5 - Common somatic genetic changes in prostate cancer (adapted from (De Marzo et al., 2007; 
Nelson et al., 2003) 
    Abbreviations: CDK, cyclin-dependent kinase. 
 
Gene and gene type Location Biochemical function Cellular function 
Tumor suppressor genes    
CDKN1B 
PTEN 
TP53 
12p12-13 
10q23.31 
17p13.1 
CDK inhibitor 
Protein/lipid phosphatase 
Transcription factor 
Cell cycle 
Signaling 
Growth arrest/apoptosis 
Oncogenes    
MYC 
AR 
8q24 
Xq11-12 
Transcription factor 
Androgen receptor 
Cell proliferation 
Signaling 
Caretaker genes    
GSTP1 11q13 Glutatione transferase Detoxification 
metabolism 
Gatekeeper genes    
NKX3.1 8p21.2 Transcription factor Cell proliferation and 
differentiation 
Other somatic changes    
PTGS2, APC, RB1, 
BRAF, PIK3CA, 
CHEK2 
Various   
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7.3.3. Chromosomal copy number changes in prostate cancer 
Advances in molecular cytogenetics and genomics facilitated the characterization of 
common genomic alterations in prostate cancer and have been established as reliable 
sources of diagnostic and prognostic information (Rose et al., 2004; Squire et al., 2011). 
Prostatic tumors contain somatic mutations, including gene deletions, amplifications and 
chromosomal rearrangements (Nelson et al., 2003). In 2006, Ribeiro et al analyzed by 
comparative genomic hybridization (CGH) the genetic profile of a consecutive series of 
prostate needle biopsies obtained prospectively from 100 PCa suspects (Ribeiro et al., 
2006a). By screening the whole genome at the same time, the advent of CGH provided the 
breakthrough in the field by having the capacity of identifying chromosomal regions affected 
by genomic imbalances (Kallioniemi et al., 1994). The pattern of copy number changes 
present in prostate tumors found by Ribeiro et al (2006) is depicted in Figure 12. Briefly, the 
most common copy number losses are 8p, 13q, 6q, 16q, 5q and 10q. Regarding the 
recurrent copy number gains, they were seen at 8q, 7q, 3q, 7p, 1q and 5p (Figure 12) 
(Ribeiro et al., 2006a). Therefore, these chromosomal regions are more prone to harbor 
oncogenes. Other more complex patterns, as well as an accumulation in the number of 
genomic gains and amplifications (Xq11.2-q12, AR), emerge in more advanced disease 
(Squire et al., 2011). 
 
Figure 12 - Genomic findings in 61 prostate carcinomas in needle biopsies done in 100 prostate cancer 
suspects. Gains and losses of genetic material are depicted along all chromosomes (X axis), with the most 
frequently altered bands being indicated (adapted from (Ribeiro et al., 2006b)). 
 
 
Moreover, Ribeiro et al (2006) has proposed a genetic pathway of PCa with two 
distinct initiating events, namely, 8p and 13q losses. These primary imbalances are then 
preferentially followed by 8q gain and 6q, 16q and 18q losses (Figure 13) which in turn are 
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followed by a set of late events that make recurrent and metastatic PCas genetically more 
complex (Ribeiro et al., 2006a). 
 
   
 
 
 
 
 
 
The fact that several of these genomic alterations have also been identified in both 
PIN and PIA lesions indicates the precursor relationship of these lesions to PCa (Shen and 
Abate-Shen, 2010).  
 
8. Chromosomal Rearrangements and Gene Fusions 
An important breakthrough in the search for novel pathogenic mechanisms in PCa 
was the finding of fusion oncogenes (Tomlins et al., 2005). The discovery that 50% of 
prostate cancers harbor recurrent gene rearrangements may enable molecular subtyping 
and identification of patients with aggressive disease (Boyd et al., 2012; Rubin et al., 2011). 
Often, these oncogenic fusions usually juxtapose a hormone-specific promoter that acts as 
an “on” switch for the oncogene, resulting in the deregulated gene expression, altered levels 
of expression or expression of chimeric proteins with transforming properties (Cooper and 
Fletcher, 2002; Rubin et al., 2011) The genes involved in these fusions are transcription 
factors, which in their altered form constitutively activate or inactivate specific target genes 
causing cellular transformation (Cooper and Fletcher, 2002). Thus, the discovery of the 
Erythroblastosis virus E26 transformation-specific (ETS) family transcription factor gene 
fusions by Tomlins et al (2005) dramatically changed the field of solid tumor biology. 
Figure 13 - Genetic model of prostate cancer progression based on genomic imbalances detected by 
comparative genomic hybridization. DNA copy number changes detected in abnormal prostate cancer 
samples were categorized as early, intermediate, or late events, according to time of occurrence and principal 
component analysis. Two potential pathways of genetic progression are proposed, one starting with 8p loss and 
the other starting with 13q loss (adapted from (Ribeiro et al., 2006a) 
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8.1. ETS family of transcription factors 
Twenty-nine human ETS transcription factor family members have been identified, 
subdivided into 5 subfamilies. All share a conserved 80-amino-acid DNA binding domain that 
recognizes the core DNA sequence 5´- GGA (A/T) - 3´ (Clark and Cooper, 2009). These 
transcription factors have the capacity to alter the expression of proteins involved in a range 
of pathways including stem cell development, cell senescence, proliferation, migration, 
apoptosis and tumorigenesis (Clark and Cooper, 2009). Although ETS gene translocations 
represent an early event in PCa, they seem to be insufficient on their own to induce cancer 
formation (Clark and Cooper, 2009). 
 
8.2. TMPRSS2 – ERG fusion 
Recent advances in the power of genomic profiling and bioinformatics have bypassed 
the technical limitations of cytogenetic analysis of solid malignancies. For example, Cancer 
Outlier Profile Analysis (COPA) has revealed recurrent chromosomal translocations between 
the ETS transcription factor family and the androgen-regulated transmembrane protease 
serine II TMPRSS2 gene (Tomlins et al., 2005). Further, these genomic rearrangements 
leading to the formation of the TMPRSS2-ETS gene fusions are the most frequent alterations 
observed in PCa (Tomlins et al., 2005). Rearrangement of the TMPRSS2 with ETS-related 
gene (ERG) has been recurrently found in about 50% of localized PCa (Albadine et al., 2009; 
Clark et al., 2008; Mao et al., 2010; Mosquera et al., 2008; Perner et al., 2006; Tomlins et al., 
2005), and in 21% of precursor HGPIN lesions (Cerveira et al., 2006), becoming the principal 
genomic alteration and a characteristic signature of prostatic malignancies (Tomlins et al., 
2009). Furthermore, this rearrangement either occurs after cancer initiation or, alternatively, 
corresponds to an early event at the transition between benign and PIN epithelium (Figure 5) 
(Perner et al., 2007). Although TMPRSS2-ERG fusions are detected less in PIN lesions than 
in tumor lesions, they are frequently detected in PIN lesions that are adjacent to fusion-
positive tumors (Carver et al., 2009; Perner et al., 2007). 
This TMPRSS2-ERG fusion (TMPRSS2 exon 1 fused to ERG exon 4) results in 
overexpression of a 5´ truncated form of the ERG transcription factor under the control of the 
androgen-responsive promoter of TMPRSS2 (Figure 14) (Clark et al., 2007; Clark and 
Cooper, 2009; Iljin et al., 2006; Perner et al., 2006; Tomlins et al., 2005; Wang et al., 2006). 
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Kezovitch et al have proposed that up-regulation of ERG in human prostate cancer 
activates cell invasion programs that subsequently displace prostate basal epithelium by the 
luminal cells and the development of PIN (Klezovitch et al., 2008). 
Wang et al characterized in detail the expression of TMPRSS2-ERG fusion mRNAs 
and correlated the isoforms expressed and expression levels with clinical outcome in cancers 
from men undergoing radical prostatectomy. There are several possible transcripts of this 
fusion gene. Expression of an isoform, in which the native ATG in exon 2 of the TMPRSS2 
gene is in frame with exon 4 of the ERG gene, was associated with clinical and pathologic 
variables of aggressive disease. Expression of other isoforms, in which the native ERG ATG 
in exon 3 was the first in-frame ATG, was associated with seminal vesicle invasion, which is 
correlated with poor outcome following radical prostatectomy. Thus, both the isoforms of 
TMPRSS2-ERG fusions expressed and expression level may affect prostate cancer 
progression (Wang et al., 2006). The mechanism behind this rearrangement is either an 
interstitial deletion in 21q22.2-3 (Iljin et al., 2006; Mertz et al., 2007; Perner et al., 2006), 
where TMPRSS2 and ERG are located ~3Mbp apart, or an insertion of the sequences 
between the two fusion partners into another chromosome  (Bott et al., 2005; Teixeira, 2008). 
However, a translocation mechanism could also be possible (Figure 15) (Liu et al., 2007; 
Teixeira, 2008). The close proximity of these two genes explains why this common 
rearrangement had not previously been detected in conventional karyotypic analyses 
(Tomlins et al., 2005). 
Figure  14 - Formation and consequences of TMPRSS2-ERG fusions. High level of truncated ERG transcript 
factor proteins is believed to cause alterations in expression of target genes (adapted from (Clark and Cooper, 
2009) 
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Figure 15 - Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene (adapted from 
(Teixeira, 2008)). 
 
Moreover, formation of these chromosomal rearrangements may be an indirect 
consequence of AR function, since studies in androgen-responsive LNCaP cells have shown 
that AR binding induces chromosomal proximity between the TMPRSS2 and ERG loci that 
can lead to formation of TMPRSS2-ERG fusions following DNA damage (Lin et al., 2009; 
Mani et al., 2009). Additionally, and even in the absence of genotoxic stress, androgen 
signaling can recruit topoisomerase II to AR-binding sites and consequently lead to induction 
of double stranded breaks (Haffner et al., 2010). At the functional level, despite the 
prevalence of these genomic rearrangements, the functional significance of TMPRSS2-ERG 
fusion and other ETS rearrangements in PCa remains not fully resolved (Shen and Abate-
Shen, 2010). 
Recently, Yu et al performed whole-genome chromatin immunoprecipitation analyses 
and concluded that ERG has the ability to bind AR downstream target genes and disrupts AR 
signaling in PCa cells through epigenetic silencing, which is consistent with a role in inhibiting 
prostate epithelial differentiation (Yu et al., 2010). Furthermore, some authors performed 
analyses of ETS activation in cell culture assays as well as transgenic mice and suggested 
that this ETS activation promotes epithelium-mesenchyme transitions (EMT) and confers 
tumor-invasive properties (Klezovitch et al., 2008; Tomlins et al., 2008; Tomlins et al., 2007b; 
Wang et al., 2008), although the effects are relatively moderate.  
With only a year of interval, both Tomlins and Klezovich reported that in transgenic 
mice, expression of truncated human ERG isoform (TrERG) resulted in a minimal or weak 
PIN phenotype after 5-6 months of age, but progression to PCa was not observed, 
suggesting that additional transforming events are required (Klezovitch et al., 2008; Tomlins 
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et al., 2007b). However, transgenic ERG overexpression in PTEN heterozygous mice 
(PTEN+/-) leads to rapid progression of HGPIN lesions to invasive carcinoma (Carver et al., 
2009). On the other hand, King et al found that the same mice background only leads to the 
development of PIN lesions and a third molecular event would be needed to promote the 
progression to prostate carcinoma (King et al., 2009). Furthermore, these authors also report 
that transgenic expression of ERG in prostate epithelium is sufficient to induce PIN lesions, 
refuting what has been previously described. Additionally, Zong et al (2009) corroborate the 
results published by Craver et al (2009), further stating that overexpression of MYC in the  
prostate glands of TrERG mice, suggesting the oncogene MYC as one of the downstream 
effectors of ERG-mediated oncogenesis (Zong et al., 2009). Moreover, and corroborating this 
interpretation, Sun et al (2008) showed that overexpression of ERG, as a result of 
TMPRSS2-ERG fusion, in VCaP cells contributes to the neoplastic process upregulating C-
MYC oncogene and by abrogating the differentiation of prostate epithelium as indicated by 
prostate epithelial markers, such as PSA, SLC45A3 and MSMB (Figure 16) (Sun et al., 
2008). 
 
 
 
 
 
 
 
 
 
 
Figure 16 - Proposed model for ERG functions in prostate cancer. ERG upregulates C-MYC and interferes 
with differentiation of prostate cancer epithelial cells (adapted from (Sun et al., 2008)). 
 
 
 
Another recent finding stated that TMPRSS2-ERG positive tumors are also correlated 
with the deletion of a small genomic region mapping to 3p14, suggestive of another 
cooperative interaction in tumorigenesis (Taylor et al., 2010). In the same year, using a high-
resolution SNP array genomic copy number analysis, Mao et al have shown a difference in 
the frequency of the TMPRSS2-ERG fusion gene between Chinese and UK-based 
populations (Mao et al., 2010). Moreover, a difference in fusion gene frequency between 
Western and Asian countries has since been supported by studies involving Korean and 
Japanese populations (Lee et al., 2010; Magi-Galluzzi et al., 2011; Miyagi et al., 2010). 
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Finally, it can be concluded that ETS rearrangements are selected primarily for their 
ability to disrupt differentiation and/or to promote cancer progression along with the 
cooperation of other transforming events (Shen and Abate-Shen, 2010). 
 
8.3. Other ETS implicated in gene fusions 
Apart from ERG, which is the most common 3´partner, three other ETS family genes, 
namely ETV1, ETV4 and ETV5, have also been found fused with TMPRSS2 or with other 
5´partners, although less frequently (Prensner and Chinnaiyan, 2009). Furthermore, Paulo et 
al (2012) has recently reported FLI1 gene as the fifth ETS transcription factor involved in 
fusion genes in PCa. By using FISH probes flanking FLI1 gene, RT-PCR and sequencing 
analyses, they could show that the 5´partner was SLC45A3 (exon 1). So, FLI1 is as a novel 
ETS transcription factor involved in gene fusions in PCa. Intratumor genetic heterogeneity of 
ETS rearrangements was occasionally found in index primary tumors (Paulo et al., 2012a). 
In addition, a number of 5´ partners, including SLC45A3, ERVK-24 (also known as 
HERVK_22), HNRPA2B1, C15orf21, NDRG1, HERPUD1, ACSL3, HERVK17, CANT1, 
DDX5, KLK2, FOXP1, EST14, and the chromosomal region 14q13.3-14q21.1 have been 
identified in ETS gene fusions (Clark and Cooper, 2009; Lapointe et al., 2007; Maher et al., 
2009; Pflueger et al., 2009; Tomlins et al., 2006). By using a paired-end RNA sequencing 
approach, Dorothee and colleagues (2009) discovered a fusion involving the already 
mentioned androgen-inducible tumor suppressor NDRG1 (N-myc downstream regulated 
gene 1) and ERG in two out of 101 PCa cases of men with localized and locally advanced 
disease (Pflueger et al., 2009). Furthermore, this fusion is predicted to encode a chimeric 
protein (Pflueger et al., 2009). Taking into account these evidences, PCa seems to be prone 
to recurrent gene fusions involving androgen-responsive genes (like TMPRSS2, SLC45A3 
and NDRG1) and ETS transcription factors (such as ERG, ETV1 and ETV4). 
Recently, Wu et al (2012) where able to identify a novel form of hybrid and aggressive 
PCa, involving the oncogene MYC, using genome and transcriptome sequencing. One 
individual was diagnosed with conventional but aggressive PCa and both primary and 
metastatic tissues were collected before hormone therapy. The transcriptome analyses 
revealed signatures of both luminal and neuroendocrine cell types. Remarkably, the 
repertoire of expressed but apparently private gene fusions, including C15orf21 (also known 
as HMGN2P46) and MYC, recapitulated this biology. This luminal-neuroendocrine tumor 
appears to represent a novel and highly aggressive case of PCa with propensity for rapid 
progression to castrate-resistance (Wu et al., 2012). Moreover, Grandori and colleagues 
suggest that the ability of overexpressed MYC to facilitate proliferation and inhibit the final 
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differentiation fits well the fact that tumors of diverse origins contain genetic rearrangements 
involving MYC family genes (Grandori et al., 2000). 
Next generation sequencing (NGS) technology has discovered novel gene fusions in 
PCa, including several non-ETS fusions such as SLC45A3-BRAF and ESRP1-RAF1 (Maher 
et al., 2009; Palanisamy et al., 2010; Pflueger et al., 2009). These gene fusions are known to 
drive tumorigenesis, despite occurring at a low frequency (<5%) compared with TMPRSS2-
ETS (Boyd et al., 2012). However, Palanisamy et al (2010) demonstrated that it is possible to 
treat cancers expressing these fusion genes with RAF or RAS/RAF/ERK pathway inhibitors 
(Palanisamy et al., 2010). 
Upon analyzing genome-wide copy number change data from 77 PCa tumors, Boyd 
et al (2012), identified a higher frequency of known TSGs – including p53, PTEN, BRCA1, 
and BRCA2 – than oncogenes at recurrent chromosome breakpoint, but have yet to 
determine whether any of these affected genes are fusion gene partners (Boyd et al., 2012; 
Mao et al., 2011). 
. 
 
9. Genetic Prognostic Factors in Prostate Cancer 
An ETS fusion gene is arguably the initial genetic event in a large subset of PCa. 
However, chromosomal instability, describing the cellular processes that increases the rate 
at which large portions of chromosomes are gained, lost or rearranged in tumors, appears to 
be more important in PCa (Squire et al., 2011). Thus, chromosome copy number changes, 
such as 8q gain (Barros-Silva et al., 2011) and 10q loss (involving PTEN) (Yoshimoto et al., 
2008), may be more relevant as prognostic factors. 
The strongest target oncogene for 8q gain is MYC, at cytoband 8q24 (Nupponen et 
al., 1998). Up to 90% of advanced tumors show 8q gain, when compared to 5% of organ 
confined tumors (Nupponen et al., 1998). It has been recently shown, using CGH, that 8q 
gain is an independent predictor of poor survival to PCa patients as patients whose tumors 
displayed this alteration are more likely to have an adverse outcome (Ribeiro et al., 2006a; 
Ribeiro et al., 2007). Given that CGH may be difficult to implement in the clinical practice, 
Ribeiro et al chose to test the feasibility of using a three-color fluorescent assay to access 8q 
status in diagnostic paraffin-embedded biopsy samples from PCa patients (Ribeiro et al., 
2007). 
Ribeiro et al (2007) used a standard FISH protocol with a dual-color probe flanking 
the gene MYC at 8q24 and a centromeric probe for chromosome 18 (CEP18) used as ploidy 
control. Relative 8q24 gain was assessed by a ratio between MYC and CEP18 signals within 
each nucleus of a representative cancer cell population. Cases categorized as having 
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relative 8q gain (whenever MYC/CEP18 ≥1.5) presented a significantly higher risk of dying 
from this malignance (Ribeiro et al., 2007). On the other hand, Barros-Silva et al (2011) 
evaluated the prognostic value of the TMPRSS2-ERG fusion gene combined with 
chromosome arm 8q relative gain in a consecutive series of diagnostic needle from patients 
with PCa. They were able to conclude, using FISH, that relative 8q gain around MYC was 
associated with poor disease-specific survival irrespective of TMPRSS2-ERG fusion gene 
status (Barros-Silva et al., 2011). Furthermore, Paulo et al, made correlation analyses with 
the clinico-pathological data and were able to show an association of ERG rearrangements 
with localized advanced disease and MYC overexpression and also an association of ETV1 
rearrangements with PTEN downregulation. MYC expression was higher and PTEN 
expression was lower in PCa with ETS rearrangements than in those without. Looking at 
ERG and ETV1 rearrangements separately, MYC was significantly upregulated only in PCa 
harboring ERG rearrangement, while PTEN was downregulated only in PCa containing ETV1 
rearrangement (Paulo et al., 2012a). This strong positive correlation found by Paulo and 
colleagues  between ERG and MYC expression in PCa with ERG rearrangement is in 
agreement with earlier reports showing that MYC is a downstream target of the 
overexpressed ERG transcription factor (Sun et al., 2008). 
In the present year, the aim of the study by Fromont et al (2013) was to analyze, in a 
large cohort of PCa tissues, the amplification status of 8q24 at the MYC locus, together with 
the protein expression of MYC and other candidate genes located at 8q24, in order to 
correlate genomic amplification and protein expression status with disease stage, 
aggressiveness and recurrence after treatment. Fromont and colleagues reached the 
conclusion that 8q24 amplification at the MYC locus (found in 29% of the cases) correlated 
with MYC protein expression and was associated with disease progression, GS and cancer 
cell proliferation. Moreover, the amplification status, but not MYC protein expression was 
strongly predictive of biochemical recurrence after radical prostatectomy, independently from 
known prognostic factors, including TNM stage and GS, and could therefore be useful to 
better predict the outcome for both intermediate-risk (pT2 and Gleason 7) and high-risk Pca 
(Fromont et al., 2013). 
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AIMS 
 
In order to better understand the role of MYC in prostate carcinogenesis, the specific 
aims of this study were: 
 To characterize the relative copy number of the MYC oncogene in a series of 
prostatectomy specimens from PCa patients with available genome-wide 
expression microarray data and ETS rearrangement status. 
  
 To evaluate the involvement of MYC in structural rearrangements in prostate 
cancer. In cases with MYC rearrangements, the involvement of the only 
known MYC 5´fusion partner, C15orf21, will be looked for. 
 
 To identify differentially expressed genes between prostate carcinomas with 
and without MYC relative copy number gain. 
 
 To look for associations between MYC structural rearrangements and copy 
number changes and clinico-pathological data in prostate cancer patients. 
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MATERIAL AND METHODS  
 
1. Sample Selection and Clinical Data 
A collection of 200 formalin-fixed paraffin-embedded (FFPE) radical prostatectomy 
specimens from patients with clinically localized prostate carcinoma treated at the 
Portuguese Oncology Institute - Porto (IPO-Porto) has been previously studied by our group 
for ETS rearrangements and MYC mRNA expression (Paulo et al., 2012a). 
Of these 200 patients, global gene-expression data has been previously obtained for 
50 by our group using the Affymetrix GeneChip Human Exon 1.0 ST arrays. Expression 
Console v1.1 software was used to obtain exon-level robust multi-array average (RMA) – 
normalized expression values for the core probe sets only (Paulo et al., 2012b). These 50 
cases were therefore selected for the evaluation of the MYC relative copy number and 
structural rearrangements by FISH. Relevant clinical data at diagnosis were obtained from 
medical records. Patient age at diagnosis ranged from 49 to 74 (mean 62, median 64, and 
median PSA value was 7.59 ng/mL (range 2.66 - 18.6). At diagnosis, 4.2% of the patients 
had the disease classified as pathological stage (pT Stage) 2a, 47.9% as pT Stage 2b, 
37.5% as pT Stage 3a and 10.4% as pT Stage 3b. 
An independent series of 4 diagnostic paraffin-embedded biopsy samples from PCa 
patients, also from IPO-Porto, for which we had earlier data indicating a 8q24 structural 
rearrangement, (Barros-Silva et al., 2011; Ribeiro et al., 2007) was also studied to evaluate 
the involvement of MYC and its known 5´fusion partner, C15orf21. 
 
2. FISH with BAC Clones 
2.1. BAC Clones Selection 
 A break-apart probe strategy using BAC clones flanking MYC was used (Table 6; 
Figure 17) to evaluate the relative copy number gain and structural rearrangements of this 
gene in the 50 radical prostatectomy specimens and to evaluate whether the 4 prostate 
biopsy specimens with 8q24 structural changes harbored a rearrangement involving MYC. 
 Additionally, to investigate the involvement of the known 5´fusion partner in gene 
fusions involving MYC, a probe strategy flanking the 5´ region of C15orf21 and the 3´region 
of MYC was also used. Bacterial artificial chromosome (BAC) clones targeting the 5´and 3´ 
regions of MYC and the 5´region of C15orf21 were selected using the University of 
 50 
 
California, Santa Cruz (UCSC) Human Genome Browser and obtained from BACPAC 
Resources Center (Oakland, California, USA) (Table 6; Figure 17). 
 
Table 6 - BAC probes used to access MYC relative copy number and structural rearrangements, as well 
as its known 5´ fusion partner, C15orf21.  
NA indicates not applicable 
 
 
 
 
Figure 17 - Representative scheme of the both FISH probe strategies flanking MYC in order to identify a 
possible rearrangement involving this gene. A) A commercial dual-color probe flanking the MYC gene. The 
400-kb probe labelled with SpectrumGreen starts 1.5Mb of the 3´ end of MYC. B) A BAC dual-color break-apart 
probe flanking MYC. The RP11-946L14 SpectrumGreen labeled probe starts 0.06Mb of the 3´end of MYC.  
 
2.2. BAC Clones Growth 
BAC clones were grown in 50 mL Falcon tubes, containing 10 mL of lysogeny broth 
(LB) medium supplemented with 12.5 µg/mL of chloramphenicol, during 16 hours, overnight, 
in an orbital shaking incubator (Figure 18). This 16h period corresponds to the transition 
from logarithmic into stationary phase of the bacterial growth. At this time, the DNA is not yet 
degraded due to overaging of the culture, as in the later stationary phase. 
 
Gene Symbol 5´Probe (SpectrumRed) 3´Probe (SpectrumGreen) 
 
MYC 
C15orf21 
 
CTD – 2313L9 
RP11 – 42E1 
 
RP11 – 946L14 
NA 
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Figure 18 - Schematic representation of the growth process of both BAC clones. 
 
 
Competent bacteria were harvested by centrifugation at 4000 rpm, during 30 minutes, 
at room temperature (RT) (Figure 19). The supernatant was then discarded and the pellet, 
was dried, upside down, for at least 15 minutes. 
 
 
 
 
10 mL LB 
+ 
20µL 
cloranfenicol 
10 mL LB 
+ 
20µL 
cloranfenicol 
+ 
RP11 – 946L14 
10 mL LB 
+ 
20µL 
cloranfenicol 
+ 
CTD – 2313L9 
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Figure 19 - Centrifugation and drying of each BAc´s pellet. 
 
                  
2.3. Plasmidic BAC DNA Extraction  
BAC DNA was extracted using the NucleoSpinR Plasmid Quick Pure Kit (MACHEREY 
- NAGEL, Dϋren, Germany) according to the manufacturer´s instructions. Briefly, the pelleted 
bacteria were resuspended in A1 resuspension buffer (supplemented with RNAse), and 
plasmid DNA was liberated from the Escherichia coli (E. coli) host cells by SDS/alkaline lysis 
(buffer A2). Buffer A3 was then added to neutralize the resulting lysate creating appropriate 
conditions for binding of plasmid DNA to the silica membrane of the NucleoSpinR Plasmid 
Column. Precipitated protein, genomic DNA, and cell debris were then pelleted by a room 
temperature centrifugation for 10 min, at 11,000 x g. The supernatant was loaded onto a 
NucleoSpinR Plasmid Column and after a 1 min, at 11, 000 x g centrifugation. To wash the 
column, ethanolic buffer A4 was used. Pure plasmid DNA was finally eluted with a slightly 
alkaline buffer (elution buffer) (5 mM Tris/HCl, pH 8.5), being then incubated during 2 min at 
room temperature, before a centrifugation for 1 min, at 11,000 x g.   
Purity and DNA concentration were measured in a NanoDrop ND 1000 
spectrophotometer (NanoDrop Technologies, USA).  
 
2.4. Amplification  
Extracted DNA was diluted to a concentration of 10ng/µL for further plasmidic DNA 
amplification. The amplification was performed by using the GenomiPhi V2 DNA amplification 
kit (WGA kit, GE, Healthcare, UK) according to the manufacturer´s instructions. In this 
reaction, 1 µL (10ng) plasmidic DNA was added to 9 µL of sample buffer. The plasmidic DNA 
was briefly heat-denaturated at 95ºC, during 3 minutes and then cooled to 4ºC in sample 
buffer containing random primers that non-specifically bind to the DNA. Then, a master mix, 
4000 rpm, RT, 30 min 
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consisting in 9 µL of reaction buffer and 1 µL of Enzyme Mix, was prepared. This master mix 
contains all the components required for DNA amplification, including DNA polymerase, 
additional random primers, dNTPs salts and buffers, and amplification proceeded during 16 
cycles, at 30ºC, for 16 hours. After this, the enzyme was heat-inactivated during 10 minutes 
incubation at 65ºC.   
 
2.5. Nick Translation 
Before hybridization, plasmidic DNA was labeled with SpectrumGreen or 
SpectrumRed (Abbott Laboratories, UK) conjugated nucleotides in nick translation reactions 
using the Nick Translation DNA Labelling System (Cat. NO. ENZ – 42910; EnzoR Life 
Sciences, USA). This reaction consisted in two cycles in which the DNA was incubated at 
15ºC, during 60 minutes, followed by an increase in temperature to 65ºC, during 5 minutes. 
About 5,5 µL of labeled BAC probe was then mixed with 5 µL of unlabeled Cot-1 DNA (Life 
Technologies, Rockville, MD), ethanol precipitated, dried and dissolved in hybridization buffer 
(Abbott Laboratories). Adequate mapping and probe specificity of all BAC clones were 
confirmed by hybridization onto normal human metaphases. 
 
2.6. FISH in tissue sections 
In this technique a labeled DNA probe is hybridized to cytological targets such as 
metaphase chromosomes, interphase nuclei, extended chromatin fibers or, more recently, 
DNA microarrays (Speicher and Carter, 2005). Such hybridization allows the identification of 
gain, loss or rearrangement of a specific gene or a set of genes. FISH in FFPE enables the 
analysis of cells maintaining tissue organization, allows observation of eventual 
heterogeneity present in the tumor and can be applied to samples not subjected to cell 
culture, obtained from fixed cells for karyotyping, paraffin blocks, aspirative cytology, etc. 
However, and like any other technique, FISH also carries some drawbacks, including probe´s 
lower penetration, tissue autofluorescence, overlapping nuclei, no intact nuclei, low efficiency 
of hybridization due to reduced or, in turn, very prolongated fixation times. 
Four- µm-thick sections from paraffin-embedded tumor blocks of 50 prostatectomy 
specimens and 4 biopsy specimens were performed onto Superfrost Plus Adhesion slides 
(Menzel–Glaser, Braunschweig, Germany). Slides were then deparaffinized in two passages 
through xylol, followed by other two passages through 100% ethanol, 10 minutes each. For 
slides pre-treatment, they were incubated in 2x SSC for 3 minutes, followed by the incubation 
with NaSCN 1M at 80ºC for 12 minutes and then rinsed in 2xSSC for 3 minutes. The 
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enzymatic digestion was made through incubation of a pepsin solution (4mg/mL) with each 
slide at 37ºC for 10 minutes in the Hybrite (Vysis) for prostatectomy and 8 minutes for biopsy 
specimens. In order to finish the digestion, the slides were placed two times in a 2xSSC 
solution for 2 minutes each, followed by an increasing series of ethanols, 70%, 85% and 
100%, for 3 minutes each. After the dehidratation, the specific probe sets were applied onto 
each sample. In the 50 prostatectomy series, 5´ and 3´MYC probes combined with a 
centromeric probe for chromosome 18 (CEP18, SpectrumAqua, Vysis) were used. For the 4 
biopsy specimens, 5´C15orf21 and 3´MYC probes were used (Table 6). Slides were placed 
in a Hybrite denaturation/hybridization system (Vysis) and co-denaturated at 80ºC for 8 
minutes, followed by hybridization for 18 hours at 37ºC. The slides were then washed in a 
2xSSC/0.5% IGEPAL (Sigma Aldrich) solution for 5 minutes and 2XSSC/0.1% IGEPAL at RT 
for 3 minutes. Slides were then counterstained with 4´, 6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories, Burlingame, California, USA). Finally, the slides were analyzed and 
fluorescent images corresponding to DAPI, Spectrum Green, Spectrum Orange, and 
Spectrum Aqua were sequentially captured in a Zeiss Axioplan fluorescence microscope 
(Zeiss, Oberkochen, Germany) coupled with a Cohu 4900 CCD camera and a CytoVision 
system version 3.9 (Applied Imaging, Santa Clara, California, USA) (Figure 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 - Schematic representation of FISH methodology in paraffin-embedded tisues. 
Relative 8q24 gain was assessed as previously described (Ribeiro et al., 2007; 
Ribeiro et al., 2006b). A ratio between MYC and CEP18 signals within each nucleus of a 
representative cancer cell population was computed for each sample. Cases were 
categorized as negative for relative 8q gain whenever MYC/CEP18 < 1.5 and as having 
relative 8q gain when MYC/CEP18 ≥1.5 (Ribeiro et al., 2007). Additionally, cases with 
MYC/CEP18 ≥ 2 ratio were deemed amplified. 
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According to the break-apart pattern of the chosen probes for the detection of MYC 
relative copy number gain (Figure 17), a prostatectomy was deemed normal when two co-
localized FISH signals were found. On the other hand, an abnormal signal pattern was 
considered representative when present in a minimum of 50 morphologically intact, non-
overlapping nuclei. 
 
3. Expression Microarrays 
DNA microarrays contain oligonucleotide or cDNA probes for measuring the 
expression of thousands of genes, to identify changes in expression between different 
biologic states (Tusher et al., 2001). However, methods are needed to determine the 
significance of these genes, so Tusher and colleagues described a statistical method, 
Significant Analysis of Microarray (SAM) that assigns a score to each gene on the basis of its 
change in expression relative to the standard deviation of repeated measurements for that 
gene. Genes with scores greater than a threshold are deemed potentially significant, and the 
percentage of such genes identified by chance is the false discovery rate (FDR). The 
threshold can be adjusted to identify smaller or larger set of genes, and FDRs are calculated 
for each set. Concerning the q-value, it is the lowest false discovery rate at which that gene 
is called significant based on the work of John Storey (Storey, 2002). It is like the commonly 
used P-value, but adapted to the analysis of a large number of genes 
Regarding SAM analysis, normalized, log-transformed and median-centered array 
results for all the  prostatectomy samples, previously obtained by our group (Paulo et al., 
2012b) were thereby submitted to two-class unpaired t-statistic method to determine the 
panel of genes with differential expression among the two FISH subgroups (presence or 
absence of 8q relative gain).  
 
 
4. Statistical Analyses 
For comparison of categorical data in the correlation analysis with clinico-pathological 
parameters, the Pearson Chi-Square test was used. Student´s t test was used for parametric 
data, when comparing two means. For non-parametric data both the Mann-Whitney U and 
the Kruskal-Walis test were used. The former was used to compare both PSA values and 
gene expression levels of MYC across the two FISH subgroups (presence or absence of 8q 
relative gain) and among the subgroup of patients with absence of 8q relative gain and 
according with ETS rearrangement status. The latter was applied when comparing the 
expression of MYC among the three subgroups of patients having 8q relative gain and 
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different ETS rearrangement status. A P value smaller than 0.05 was considered statistically 
significant. Statistical analyses were performed using the Statistical Package for Social 
Sciences software, version 20.0 (SPSS Inc., Chicago, IL).  
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RESULTS 
 
1. Relative MYC Copy Number 
 
The starting point of this study was a subset of 50 prostate carcinomas with available 
global gene-expression data using the Affymetrix GeneChip Human Exon 1.0 ST arrays, 
(Paulo et al., 2012b). The relative copy number of MYC in this cohort was assessed by FISH. 
Of these 50 cases, 2 were considered not analyzable. Overall, tumor cell populations with 
MYC copy number increase were found in 20 PCas. Of these, 3 PCas had a MYC/CEP18 
ratio lower than 1.5, being therefore considered negative for relative 8q gain (Table 1 on 
appendix). Of the 17 PCas with relative 8q gain (MYC/CEP18≥1.5), 6 displayed MYC 
amplification (MYC/CEP18 ≥ 2) (Figure 21). 
 
 
 
 
 
 
 
 
 
 
Figure 21 - Representative FISH images from selected prostatectomy specimens analyzed with BAC 
clones targeting 5´ and 3´MYC, labeled red and green respectively, and with chromosome 18 centromeric 
probe (aqua). A) Nuclei with two co-localized (red and green) signals of MYC, and two centromeric signals 
(aqua) representing a normal result. B) Nuclei showing three co-localized signals of MYC and three centromeric 
signals of chromosome 18, representing no relative copy number gain of MYC. C) Nuclei presenting relative copy 
number gain of MYC, illustrated by three co-localized signals of MYC and two centromeric signals of chromosome 
18 (MYC/CEP18=1.5). D) Nuclei showing two to four co-localized signals of MYC, two to three additional red 
signals and two to four centromeric signals of chromosome 18 (MYC/CEP18>1.5). 
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2. MYC Structural Rearrangements 
 
Deletion of 3´MYC was found in two prostatectomy specimens and a 5´MYC deletion 
was found in one additional case (Table 7). Whereas both indicate a structural 
rearrangement of the MYC gene, the latter is compatible with a MYC rearrangement 
involving a 5´ fusion partner (Figure 22).  
 
  
 
 
 
 
 
 
 
To search for additional cases with possible gene fusions involving MYC, we studied 
an independent set of 4 biopsy specimens in which we had earlier evidence of 8q24 
structural rearrangements using commercially available probes relatively far apart from MYC 
(Barros-Silva et al., 2011; Ribeiro et al., 2007). In the current study, we used BAC probes 
with the particularity of closely flanking MYC, therefore allowing to evaluate if this gene is 
involved in structural rearrangements (Figure 17). The results are summarized in Table 7 
and illustrated by Figure 23. Although results represented on Figure 22 are illustrative of the 
most frequent tumor cell populations, more than one single genetic alteration was observed 
in the biopsy specimens, a normal phenomenon due to the high heterogeneity present in 
prostate tumors. 
 
Figure 22 - Representative FISH image from a selected prostatectomy specimen, P279T, analyzed with 
BAC clones targeting 5´ and 3´MYC, labeled red and green respectively, and with chromosome 18 
centromeric probe. This figure illustrates nuclei with two co-localized signals of MYC, one additional green 
signal, indicating a MYC structural rearrangement, and two centromeric signals of chromosome 18. 
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Table 7 - Experimental findings of a rearrangement involving MYC in the three prostatectomy specimens 
and in the 4 biopsy specimens. 
F indicates fusion (co-localization); G, spectrum green, R, spectrum red. 
 
We then looked for the involvement of the only known MYC 5´fusion partner, 
C15orf21. The analysis of these prostate biopsy specimens did not indicate a chromosomal 
rearrangement typical of a fusion gene involving the C15orf21 gene, as no co-localization of 
the probes flanking C15orf21 and MYC was found (Figure 24). 
Sample FISH 
P279T 
P268T 
P499T 
A - 1870/98 
B - 2643/98 
C - 3249/99 
D and E - 7399/98 
2F, 1G, 2Aq 
(1-4)F, (2-4)R, (1-4)Aq 
(3-8)F, (1-2)R, (2-6)Aq 
Amp R 
(1-3)F, (1-2)R 
(2-3)F, 1R, 1G 
1F, 2R, 1G/ 2F, 4R, 2G 
Figure 23 - Representative FISH images from 4 selected biopsy speciments analyzed with BAC clones 
targeting 5´ and 3´MYC, labeled red and green, respectively. A) Nuclei with amplification of 5´MYC region. B) 
Nucleus showing two co-localized signals of MYC and two additional red signals. C) Nucleus presenting two co-
localized signals of MYC and one green and one red signal far apart.  In this particular case, the green signal is 
localized relatively near from the two co-localized signals of  MYC. D) Nucleus showing one co-localized signal of 
MYC, one green signal and two isolated red signals. E) Nucleus with two co-localized signals of MYC, two green 
signals and four red signals. Both D) and E) images represent tumor cells from the same biopsy specimen. 
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3. Differentially Expressed Genes According to 8q Status 
 
The application of Significance Analysis of Microarrays (SAM) in our data allowed the 
identification of three significantly overexpressed genes in the subgroup with 8q relative gain, 
namely IKZF2, CDON, and GPRC5A (Figure 25), with a FDR = 0% and a q-value = 0.  
According with this analysis, MYC was not found to be differentially expressed among the 
two subgroups of patients (q-value = 35). Apart from MYC, ERG and ETV1 are the two ETS 
genes most commonly involved in gene fusions in PCa and were therefore included in the 
figure.  
 
 
 
 
 
 
 
 
Figure 25 - Differentially expressed genes among sample subgroups: no 8q gain versus 8q gain 
discovered by SAM. Genes overexpressed in the 8q gain subgroup are highlighted in bold (IKZF2, CDON, 
GPRC5). For illustrative purpose, expression of ERG, ETV1, and MYC are also displayed in the figure. Each cell 
represents a sample and its expression was defined by different colors. Red represents the samples 
overexpressed and dark green corresponds to the samples with lower expression. 
 
 
 
 
 
 
Figure 24 - Representative FISH images from 4 selected biopsy speciments analyzed with BAC clones 
targeting 5´C15orf21 and 3´MYC, labeled red and green, respectively. A) Nuclei presenting two aditional 
green signals and two red signals. B) Nuclei with two green signals and a 5´ C15orf21 deletion, marked by the 
absence of one red signal. C) Nuclei presenting three green signals of MYC and two C15orf21 red signals. D) 
Nuclei showing two additional green signals and two red signals. 
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3.1. MYC as a target gene of 8q24 copy number gain 
 
As stated above, SAM analysis excluded MYC as a significantly overexpressed gene 
in PCa with 8q gain. However, given that it is commonly stated in the literature the 
association of MYC and 8q gain (Fromont et al., 2013; Jenkins et al., 1997; Nupponen et al., 
1998), we decided to look at it using conventional statistical approaches, including the Mann-
Whitney U test. 
Although there is indeed a higher expression of MYC in the 8q gain subgroup, the 
difference is only borderline for statistical significance (P=0.051) (Figure 26), which is 
compatible with the SAM analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 – Differential expression of MYC across the two patient subgroups (no 8q gain and 8q gain) 
previously stratified by the FISH analysis of the 48 prostate carcinomas. 
 
3.2. Correlation of 8q24 and ETS rearrangement status 
 
To look for the possible effect of ETS rearrangements status in MYC expression, we 
compared three groups of patients, harboring no ETS rearrangements, an ERG 
rearrangement, or other ETS rearrangements (ETV1, ETV4 and ETV5) in the presence 
(Figure 27) or absence (Figure 28) of 8q gain.  
Considering patients with 8q gain, no differences in MYC expression were found 
among the three ETS subgroups (P= 0.852).  
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Figure 27 - Differential expression of MYC across the three subgroups stratified by both 8q relative gain 
and ETS rearrangement status. 
 
On the other hand, in patients with no 8q gain, differential MYC expression was 
observed among the different ETS groups (P=0.048). Paired comparisons showed that MYC 
expression was significantly higher in patients with ETS rearrangements other than ERG 
(P=0.021) compared to ETS- patients. Although patients with ERG rearrangements had 
higher MYC expression than ETS- patients, the difference was not statistically different (P= 
0.118).  
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Figure 28 - Differential expression of MYC across the three subgroups stratified by both no 8q relative 
gain and ETS rearrangement status. 
  
 
 
4. Relative 8q Gain and Clinico-Pathological Associations 
 
Statistical comparisons with clinico-pathological data showed no association of 8q 
relative gain with age (P=0.757), PSA level at diagnosis (P=0.271), GS (P=0.303), and pT 
stage (P=0.483). All the clinico-pathological parameters are summarized in Table 8. 
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Table 8 – Correlation analysis of the FISH results for the presence or absence of the 8q relative gain with 
clinico-pathological parameters. 
 
                                     8q  relative gain 
Clinical parameters - + P 
 
Age (±std) 
 
62.20 ± 6.75 
 
62.67 ± 5.85 
 
0.757  
PSA at diagnosis (median) 7.45 7.80 0.271  
Gleason score    
GS<7 11 (73.3%) 4 (26.7%) 0.303 
GS=7 20 (62.5%) 12 (37.5%)  
GS>7 0 (0.0%) 1 (100.0%)  
pT Stage    
2a 2 (100.0%) 0 (0.0%) 0.483 
2b 15 (65.2%) 8 (34.8%)  
3a 12 (66.7%) 6 (33.3%)  
3b 2 (40.0%) 3 (60.0%)  
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DISCUSSION  
 
Gene fusions involving the ETS transcription factor family of genes are a recurrent 
feature of PCa. These gene aberrations, caused by chromosomal structural abnormalities, 
originate fusion transcripts that lead to overexpression of N-truncated ETS proteins, or, more 
rarely, to full-length ETS proteins or chimeric fusion proteins. In 2005, Tomlins reported the 
fusion of the prostate-specific, androgen-regulated promoter region of TMPRSS2 gene with 
ERG, the most common ETS rearrangement, being present in 50% of the localized PCas, 
and in 21% of precursor HGPIN neoplasia lesions (Albadine et al., 2009; Cerveira et al., 
2006; Clark et al., 2007; Liu et al., 2007; Mao et al., 2010; Mosquera et al., 2008; Perner et 
al., 2006; Soller et al., 2006; Tomlins et al., 2005). Other rarer fusion events can occur 
involving the ETV1 (Attard et al., 2008; Hermans et al., 2008; Tomlins et al., 2007a; Tomlins 
et al., 2005), ETV4 (Tomlins et al., 2006), ETV5 (Helgeson et al., 2008), and FLI1 genes 
(Paulo et al., 2012a). Besides the TMPRSS2, several other 5´ ETS fusion partners have also 
been described, namely HERPUD1, HERVK17, SLC45A3, ERVK-24 (also known as 
HERVK_22q), HNRPA2B1, C15orf21, NDRG1, CANT1, DDX5, KLK2, FOXP1, EST14, 
ACSL3, and the chromosomal region 14q13.3-14q21.1 (Lapointe et al., 2007; Pflueger et al., 
2009; Tomlins et al., 2006). Although TMPRSS2-ERG is suggested to be an early event, 
presumably occurring at the transition between benign and PIN epithelium (Perner et al., 
2007), secondary chromosome changes, such as 8q gain comprising MYC, have been 
shown to be one of the best candidate genetic prognostic factors. It is remarkable that 8q 
gain detected in diagnostic needle biopsies of PCa suspects, by either CGH or FISH, is 
significantly associated with death from disease (Ribeiro et al., 2006b). Additionally, it has 
been shown that 8q gain predicts poor disease-specific survival independently of the 
presence of TMPRSS2-ERG fusion gene (Barros-Silva et al., 2011). The recent discovery of 
a novel and highly aggressive hybrid case of PCa, harboring the novel C15orf21-MYC fusion 
gene, highlights the potential involvement of the MYC oncogene in prostate carcinogenesis 
by several mechanisms. However, the role of MYC in prostatic carcinogenesis is still poorly 
understood. 
To increase our knowledge on the involvement of the MYC oncogene in prostate 
carcinogenesis, we evaluated in this study MYC relative copy number and structural 
rearrangements in 50 prostatectomy specimens of patients with available genome-wide 
microarray expression data and clinic-pathological parameters. In addition, we evaluated 
further the involvement of MYC in 4 PCa biopsy specimens with available data indicating a 
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structural rearrangement in 8q24. In case of validation of MYC rearrangements, the 
involvement of the only known MYC 5´fusion partner, C15orf21, will be checked. 
 
1. MYC Relative Copy Number Gain 
 
MYC relative copy number was evaluated in 50 prostatectomy specimens using 
FISH. The break-apart probe strategy using BAC clones closely flanking MYC (8q24) is 
expected to identify both prostate carcinomas with 8q gain and structural rearrangements 
involving MYC, and the dual-color labeling enables the scoring of copy number changes and 
structural rearrangements in archival prostatectomy specimens. To control for ploidy in each 
case, we chose a chromosome 18 probe, because the centromeric region of this 
chromosome is rarely affected in PCa, as opposed to other commercial available 
SpectrumAqua probes (chromosomes 8, 10, and 17) (Ribeiro et al., 2006b).  
Overall, tumor cell populations with MYC relative copy number increase 
(MYC/CEP18≥1.5) were found in 35% of the prostate carcinomas, and of these 6 cases 
displayed MYC amplification (MYC/CEP18>2). Jenkins et al (1997) and Fromont et al (2013) 
reported similar results as ours. The former studied twenty-five prostatectomy and pelvic 
lymphadenectomy specimens and analyzed, by FISH, the relative extra MYC copy number. 
These authors used DNA probes for the centromere region of chromosome 8 (CEP8) and for 
the 8q24 (MYC) region and found relative MYC copy number increase (MYC/CEP8≥1.5) in 
11% of the patients (Jenkins et al., 1997). On the other hand, the cohort studied by Fromont 
and colleagues (2013) was composed by 202 prostatectomy specimens, and they also 
evaluated by FISH the relative MYC copy number increase by using a commercial dual-color 
probe (MYC/CEN8) that consists in a mixture of an orange fluorochrome direct-labeled probe 
specific for the alpha satellite centromeric region of chromosome 8 (D8Z2) and a green 
fluorochrome direct labeled SPEC MYC probe specific for the MYC gene at 8q24. These 
authors observed that 29% of the tumors tested showed increase of 8q24 at the MYC locus 
(MYC/CEN8≥1.5). 
 
 
2. MYC Structural Rearrangements 
 
The same probe strategy used to evaluate MYC copy number was able to identify 
structural rearrangements involving this gene. In fact, two cases with a 3´MYC deletion and 
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one case with a 5´MYC deletion were found in the series of 50 prostatectomy specimens 
evaluated for MYC copy number changes, with the latter being the best candidate for a MYC 
rearrangement involving a 5´ fusion partner.  
Additionally, our group has analyzed by FISH a retrospective series of paraffin-
embedded biopsies from 60 PCa patients for relative 8q24 gain (Ribeiro et al., 2007). For 
each of the sixty biopsy samples, a commercial dual-color probe flanking the MYC gene at 
8q24 and a CEP18 probe labeled with SpectrumAqua were used in each sample. The MYC 
probe set consists of a ~277kb SpectrumOrange labeled probe and a ~400kb probe labeled 
with SpectrumGreen (Figure 17). The dual-color labeling of that probe allowed the detection 
of rearrangements presumably involving MYC in 4 biopsy specimens that include gain or loss 
of the individual 3´MYC and 5´MYC probes (Ribeiro et al., 2007). However, other genes, 
such as plasmocytoma variant translocation 1 gene (PVT1) and transmembrane protein 75 
(TMEM75) gene, reside in this locus and therefore might be possible candidates to be 
involved in the breakpoint. Due to the long distance between the dual-color flanking probes, it 
was not clear where the breakpoint had occurred. Our strategy in this study was therefore 
the choice of a break-apart probe using BAC clones closely flanking MYC that could provide 
a more precise location of the breakpoint region. The MYC BAC probe set consists of a 
~166kb SpectrumRed labeled probe and a ~172kb probe labeled with SpectrumGreen 
(Figure 17). Our results corroborated the initial suspiction of Ribeiro and colleagues (2007) 
and the mentioned gain or loss of the individual 3´MYC and 5´MYC probes was 
demonstrated by a split between the green and red signals (3´MYC and 5´MYC regions, 
respectively), reflected either by a deletion of the 3´MYC (Figure 23D) or by the increase 
copy number of the 5´MYC region (Figure 23A and E).  
 
4. Evaluation of a Possible 5´ Fusion Partner of MYC 
 
Gene fusions involving the ETS transcription factor family of genes are a recurrent 
feature in PCa and the 5´fusion partner C15orf21 gene has been reported to be involved in 
these ETS gene fusions, namely with ETV1 (Barros-Silva et al., 2013; Lapointe et al., 2007; 
Pflueger et al., 2009; Tomlins et al., 2006). However, C15orf21 has recently been reported to 
be also involved in gene fusions with MYC (Wu et al., 2012). These authors, using genome 
and transcriptome sequencing, identified a novel form of hybrid and aggressive PCa, 
involving the oncogene MYC. The transcriptome analyses revealed signatures of both 
luminal and neuroendocrine cell types. Remarkably, the repertoire of expressed but 
apparently private gene fusions, including C15orf21 and MYC, recapitulated this biology. 
This hybrid luminal-neuroendocrine tumor appears to represent a novel and highly 
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aggressive case of PCa with propensity for rapid progression to castrate-resistance. After 
confirming the structural rearrangement involving MYC in the 4 biopsy specimens, we then 
looked for the involvement of the only known 5´fusion partner of MYC, C15orf21. However, 
our results did not confirm that C15orf21 was the 5´fusion partner of MYC, as no co-
localization of the probes flanking C15orf21 and MYC was found. The presumed 5´fusion 
partner of MYC in these cases remains therefore unknown. 
 
5.  Overexpressed Genes Associated with Relative MYC Gain 
 
The SAM analysis identified three significantly overexpressed genes, namely IKZF2, 
CDON, and GPRC5A, in the MYC relative gain subgroup of patients (Figure 25). IKZF2, 
ikaros family zinc finger 2, also known as helios, is an hematopoietic-specific transcription 
factor involved in the regulation of lymphocyte development. It is also known that this protein 
forms homo and hetero-dimers with other ikaros family members, and is thought to function 
predominantly in early hematopoietic development. Ikaros was found as a marker of T-cell 
activation and proliferation (Akimova et al., 2011) and a short isoform of this gene has been 
recently reported to be overexpressed in a patient with T-cell acute lymphoblastic leukemia 
(Nakase et al., 2002). On the other hand, ikaros has been found to be involved in a gene 
fusion involving B-cell CLL/lymphoma 11B (zinc finger protein) (BCL11B) gene in an adult T-
cell leukemia patient (Fujimoto et al., 2012). Further, this transcription factor has been related 
with lymphoid malignancies (Rebollo and Schmitt, 2003) and with both non-Hodgking and 
Hodgkin lymphoma (Antica et al., 2008).  
Cell-adhesion associated, oncogene regulated (CDON) encodes a cell surface 
receptor that is a member of the immunoglobulin superfamily. The encoded protein, CDO, 
being a member of a cell surface receptor complex, mediates cell-cell interactions between 
muscle precursor cells and positively regulates myogenesis. A recent study published by 
Hayashi and colleagues (2011) showed, by using quantitative RT-PCR  analysis, 
overexpression of this gene in about 83% of PCa tissues, and its expression is involved in 
tumor cell growth and invasion. Moreover, knockdown of CDON in DU145 cells induced 5 – 
fluorouracil-induced apoptosis and inhibited invasion ability, suggesting that this gene has a 
high potential as a therapeutic target for PCa (Hayashi et al., 2011) However, they did not 
test the association of CDON with MYC copy number  
Lastly, the protein-coupled receptor, family C, group 5, member A (GPRC5A) gene, 
being a member of the type 3G protein-coupling receptor family, may be involved in the 
interaction between retinoic acid an G protein signaling pathways. Retinoic acid plays a 
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critical role in development, cellular growth and differentiation and this gene may also play a 
role in both embryonic development and epithelial cell differentiation. Jörissen and 
colleagues (2009) conducted a systematic analysis of GPRC5A (also known as RAI3) 
expression in normal and cancerous human breast tissue at both mRNA and protein levels 
and reported, based on cDNA dot blot and immunohistochemistry experiments, that both 
RAI3 mRNA and RAI3  protein were abundantly expressed in human breast carcinoma 
(Jorissen et al., 2009). However, this retinoic acid-inducible gene was identified by Tao et al 
(2007) as a new lung tumor suppressor gene (Tao et al., 2007). Moreover, GPRC5A tumor 
suppressor loss of expression was found conserved, prevalent and associated with survival 
in human lung adenocarcinoma (Kadara et al., 2010). It is, however, important to note that 
GPRC5A expression was also high in normal prostate tissue. 
 
4.1. MYC as a target gene of 8q24 copy number gain 
SAM analysis revealed that MYC was not differentially expressed among the two 
subgroups previously stratified by FISH (presence or absence of 8q relative gain), (FDR = 
0%; q-value = 35). Given that some authors have associated 8q gain with MYC 
overexpression in a subset of prostate adenocarcinoma cases (Fromont et al., 2013; Jenkins 
et al., 1997; Nupponen et al., 1998; Nupponen et al., 1999), we also evaluated the 
expression of MYC among the same two subgroups of patients, and indeed there was a 
tendency (P = 0.051) for an association between MYC copy number gain and higher 
expression of this gene. Although the method of obtaining the MYC gene expression levels 
was different from ours, Gurel et al (2008) compared MYC protein levels in PCa by 
semiquantitative image analysis of immunohistochemistry stained specimens, and did not 
find a correlation between gain of 8q24 by FISH and MYC expression level (Gurel et al., 
2008). Furthermore, gain of 8q24 is rare in PIN lesions and localized low-grade prostate 
adenocarcinomas, yet MYC overexpression is common on these lesions. Moreover, other 
genes, including TRPS1, EIF3S3, RAD21, KIAA0916, and PSCA, reside in or near this locus 
and have been put forth as potential targets of 8q amplification (Nupponen et al., 1999; 
Porkka et al., 2004; Reiter et al., 2000; Saramaki et al., 2001; Tsuchiya et al., 2002; van Duin 
et al., 2005). 
Sun et al (2008) reported that in VCaP cells the overexpressed ERG, as a result of 
harboring a TMPRSS2-ERG fusion, upregulates C-MYC oncogene (Sun et al., 2008). In 
order to look for the possible effect of ETS rearrangements status in MYC expression, we 
compared three groups of patients, harboring no ETS rearrangements, harboring an ERG 
fusion gene, or other ETS rearrangements (ETV1, ETV4 and ETV5) in the presence or 
absence of 8q gain. Regarding the patients with 8q gain, our results did not show a 
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significant differential expression of MYC across the three ETS subgroups (P = 0.852). 
Concerning the patients with no 8q relative gain, a differential MYC expression was observed 
among the different ETS subgroups (P = 0.048), and its expression was higher in the other 
ETS+ subgroup of patients. We then compared the subgroup of patients harboring other 
ETS+ rearrangements with the other two subgroups (harboring no ETS rearrangements, and 
harboring only ERG rearrangements), and our results showed that, in the absence of 8q 
relative gain, the other ETS genes, but not ERG, were associated with increased expression 
of MYC (P = 0.021). Despite the apparently overlapping oncogenic potential of ERG and 
ETV1 gene fusions, it has not been established whether different ETS transcription factors 
have specific or shared downstream targets. In order to address this issue, Paulo and 
colleagues (2012), by using exon-level expression arrays in a series of 50 PCa presenting 
different ETS rearrangements (21 samples with ERG rearrangements, 13 samples 
presenting ETV1 rearrangements, 2 sample each harboring ETV4 and ETV5 
rearrangements, and 14 samples without ETS rearrangements), concluded that both ERG 
and ETV1 regulate specific and shared target genes (Paulo et al., 2012b). Moreover, when 
the expression profiles of the two PCa with ETV4 and ETV5 rearrangements where included 
in the hierarchical clustering, they clustered among the ETV1-positive PCa samples, 
suggesting that ETV4 and ETV5 might be, at least in part, shared by ETV1, something that 
was expected since these genes belong to the same PEA3 family of transcription factors 
(Hollenhorst et al., 2007; Paulo et al., 2012b). 
 
5. Clinico-Pathologic Associations with Relative MYC Gain 
 
We did not find a statistically significant association of the clinico-pathologic 
parameters with 8q relative gain. It is however interesting to note that the frequency of 8q 
gains increased with the degree of indifferentiation (ie, higher Gleason scores). Barros-Silva 
et al (2011) have previously reported that relative 8q gain was less frequent in low GS 
prostate tumors (Barros-Silva et al., 2011). Regarding the disease progression (pT Stage), 
none of the pT2a prostatectomy specimens had 8q gain, rising to about 30% in pT2b and 
pT3a, and finally to 60% of pT3b patients. Our findings are in agreement with the already 
stated by Ribeiro et al (2006), that 8q gain appears at an intermediate event, in the transition 
of organ confined to locally invasive PCa (Ribeiro et al., 2006a). 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 Relative copy number gain of MYC was found in 35% of the prostatectomy 
specimens, and involvement of this gene in a structural rearrangement with a 
unknown 5´fusion partner was only found in one prostatectomy specimen. In order to 
search for possible 5´ MYC fusion partners, we could perform 5´rapid amplification of 
cDNA ends (5´RACE) as we already have extracted RNA for this prostatectomy 
specimen. 
 
 Although we confirmed the involvement of MYC in the 4 PCa biopsy specimens with 
available data indicating a structural rearrangement in 8q24, the only known MYC 5’ 
fusion partner, C15orf21, was excluded as the 5’ fusion partner in this case. 
 
 The SAM analysis highlighted three significantly overexpressed genes in subgroup 
with relative MYC copy number gain, namely IKZF2, CDON and GPRC5A3. Since 
CDON has already been reported to be overexpressed in PCa tissues, it will be 
interesting to confirm if CDON overexpression can also be detectable at the protein 
level by immunohistochemistry.  
 
 Considering patients with 8q gain, no differences in MYC expression were found 
among different ETS molecular subtypes. On the other hand, in patients with no 8q 
gain, differential MYC expression was observed among the three ETS molecular 
subtypes, being MYC expression higher in the group of patients harboring ETS 
rearrangements other than ERG.  
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 Table 1 - Summary of the experimental findings in 48 prostate tumors 
Sample      MYC expression (array) FISH 
P279T 10,04590 2F, 1G, 2Aq 
P291T 9,81674 3F, 2Aq 
P272T 9,79870 2F, 2Aq 
P488T 9,79230 2F, 2Aq 
P298T 9,77782                3F, 1Aq 
P261T 9,77219 2F, 2Aq 
P456T 9,67331 3F, 2Aq 
P288T 9,65540 2F, 2Aq 
P300T 9,54934 3F, 2Aq 
P263T 9,54788 2F, 2Aq 
P281T 9,51871 3F, 1Aq 
P356T 9,51362 3F, 2Aq 
P467T 9,50377 2F, 2Aq 
P451T 9,45699 2F, 2Aq 
P487T 9,45084 2F, 2Aq 
P268T 9,39545 (1-4)F, (2-4)R, (1-4)Aq 
P209T 9,38808 (3F, 2Aq); 3F, 1Aq 
P499T 9,34923 (3-8)F, (1-2)R, (2-6)Aq 
P257T 9,34543 2F, 2Aq 
P542T 9,34401 2F, 2Aq 
P276T 9,32716 2F, 2Aq 
P238T 9,30989 3F, 1Aq 
P522T 9,29374 2F, 2Aq 
P274T 9,27316 2F, 2Aq 
P301T 9,25564 4F, 2Aq 
P289T 9,24508 2F, 2Aq 
P307T 9,22398 3F, 3Aq 
P303T 9,19531 3F, 2Aq 
P351T 9,18999 2F, 2Aq 
P264T 9,12502 2F, 2Aq 
P525T 9,11501 2F, 2Aq 
P229T 9,10989 2F, 2Aq 
P344T 9,10117 3F;2Aq 
P241T 9,03349 3F, 2Aq 
P262T 8,92137 2F, 2Aq 
P227T 8,89570 2F; 2Aq 
P297T 8,84844 2F; 2Aq 
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P265T 8,77253 2F, 2Aq 
P230T 8,72831 3F, 2Aq 
P470T 8,69278 2F, 2Aq 
P461T 8,61359 2F, 2Aq 
P251T 8,59438 2F,2Aq 
P305T 8,56142 3F, 3Aq 
P242T 8,48194 2F, 2Aq 
P294T 8,46684 3F, 3Aq 
P228T 7,86252 2F, 2Aq 
P245T 7,70471 (7-15)F, (2-4)Aq 
P223T 7,45986 2F, 2Aq 
 
CEP 18 indicates centromeric probe for chromosome 18; F, fusion; Aq, spectrum aqua; G, spectrum 
green; R, spectrum red, n.a., not analyzable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
